CN111574577A - 鹅去氧胆酸衍生物 - Google Patents
鹅去氧胆酸衍生物 Download PDFInfo
- Publication number
- CN111574577A CN111574577A CN202010345654.3A CN202010345654A CN111574577A CN 111574577 A CN111574577 A CN 111574577A CN 202010345654 A CN202010345654 A CN 202010345654A CN 111574577 A CN111574577 A CN 111574577A
- Authority
- CN
- China
- Prior art keywords
- compound
- mmol
- added
- nhs
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002844 chenodeoxycholic acid derivative Substances 0.000 title description 3
- 150000001801 chenodeoxycholic acids Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 379
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 150000003254 radicals Chemical class 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 45
- 201000010099 disease Diseases 0.000 abstract description 37
- 239000003814 drug Substances 0.000 abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 323
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 164
- 239000000243 solution Substances 0.000 description 138
- 238000006243 chemical reaction Methods 0.000 description 137
- 238000005160 1H NMR spectroscopy Methods 0.000 description 130
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- 235000019439 ethyl acetate Nutrition 0.000 description 108
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 88
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 75
- 239000012044 organic layer Substances 0.000 description 64
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 49
- 239000002904 solvent Substances 0.000 description 45
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 43
- 238000004809 thin layer chromatography Methods 0.000 description 43
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- 239000010410 layer Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- 125000005842 heteroatom Chemical group 0.000 description 31
- 229910052757 nitrogen Inorganic materials 0.000 description 31
- 239000003208 petroleum Substances 0.000 description 31
- 229910052938 sodium sulfate Inorganic materials 0.000 description 30
- 235000011152 sodium sulphate Nutrition 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 29
- 239000012043 crude product Substances 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000003756 stirring Methods 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 102100038495 Bile acid receptor Human genes 0.000 description 22
- -1 amino-substituted radical Chemical class 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 238000004440 column chromatography Methods 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 125000006413 ring segment Chemical group 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 10
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 125000004404 heteroalkyl group Chemical group 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 238000012746 preparative thin layer chromatography Methods 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 208000000014 Ureteral Calculi Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 5
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010008635 Cholestasis Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 4
- 230000008484 agonism Effects 0.000 description 4
- 238000003016 alphascreen Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 4
- 210000003445 biliary tract Anatomy 0.000 description 4
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N carbon disulfide Substances S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 4
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- 208000031868 Calculus ureteric Diseases 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- 102000007451 Steroid Receptors Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000005271 biliary atresia Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 239000002812 cholic acid derivative Substances 0.000 description 2
- 150000001842 cholic acids Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- AQMHNCQZLQUNJI-UHFFFAOYSA-N [CH2]CCCCCC Chemical compound [CH2]CCCCCC AQMHNCQZLQUNJI-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- JJNHBFYGCSOONU-UHFFFAOYSA-M carbanide;cyclopenta-1,3-diene;dimethylaluminum;titanium(4+);chloride Chemical compound [CH3-].[Ti+3]Cl.C[Al]C.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 JJNHBFYGCSOONU-UHFFFAOYSA-M 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- NKRNGKIEDAVMHL-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1 NKRNGKIEDAVMHL-UHFFFAOYSA-L 0.000 description 1
- WHFKIZXBVFEJGA-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 WHFKIZXBVFEJGA-UHFFFAOYSA-L 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 108010057988 ecdysone receptor Proteins 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- WWTULTKUWBKVGV-UHFFFAOYSA-M potassium;3-methoxy-3-oxopropanoate Chemical compound [K+].COC(=O)CC([O-])=O WWTULTKUWBKVGV-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- YICLNJXQEZYMHM-UHFFFAOYSA-N tert-butyl 1,1-dioxo-2H-1,2,5-thiadiazole-5-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1S(NC=C1)(=O)=O YICLNJXQEZYMHM-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/001—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class spiro-linked
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0073—Sulfur-containing hetero ring
- C07J71/0094—Sulfur-containing hetero ring containing sulfur and nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请公开了式Ⅰ、式Ⅱ、式Ⅲ、式Ⅳ或式Ⅴ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐,并公开了其在制备治疗FXR相关疾病药物中的应用。
Description
本申请是以下申请的分案申请:申请日2016年04月29日;申请号:201680024495.9;发明名称:“鹅去氧胆酸衍生物”。
发明领域
本申请涉及医药领域。具体而言,本申请涉及式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐,并涉及其在制备治疗FXR相关疾病药物中的应用。
背景技术
尼酯X受体(FXR)是一种最初从大鼠肺cDNA文库中鉴定的孤儿核受体(BM.Forman,et al.,Cell 81:687-693(1995)),其与昆虫蜕皮激素受体密切相关。FXR是包括类固醇,类维生素A,和甲状腺激素受体的配基-激活转录因子核受体家族的成员(DJ.Mangelsdorf,etal.,Cell 83:841-850(1995))。Northern和原位分析显示FXR在肺,肠,肾,和肾上腺中大量表达(BM.Formanet al.,Cell 81:687-693(1995)和W。Seolet al.,Mol.Endocrinnol。9:72-85(1995))。FXR与9-顺式维生素A酸受体(RXR)形成异源二聚体与DNA结合。FXR/RXR异源二聚体优先与由共有AG(G/T)TCA的双核受体半位点组成的成分结合,其形成反向重复并被单一核苷分离(IR-1模体)(BM.Forman,et al.,Cell 81:687-693(1995))。然而,这些化合物无法激活小鼠和人类FXR,使得内源性FXR配基的自然性还不确定。一些自然发生的胆酸在生理浓度下结合并激活FXR(PCTWO 00/37077,2000年6月29日出版))。如此所述,作为FXR配基的胆酸包括鹅脱氧胆酸(CDCA),脱氧胆酸(DCA),石胆酸(LCA),和这些胆酸的牛磺酸及氨基乙酸共轭物。
WO-2005082925公开了INT747在制备治疗FXR相关疾病中的应用。
发明概述
本申请的一方面提供式Ⅰ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐:
其中,
R7、R8和R9分别独立地选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基,任选地,R8和R9可连接在一起形成一个3~6元环;或者,R9选自H,R7和R8与所连碳原子形成任选被1、2、3、4或5个R取代的5~6元杂芳环或C3-6环烷基;
上述R分别独立地选自卤素、CN、OH、NH2、SH,或任选被1、2、3、4或5个R’取代的C1-3烷基、C1-3杂烷基;
上述R’选自卤素、CN、OH、NH2、SH、Me或三氟甲基;
本申请的另一方面提供式Ⅱ、式III或式IV所示化合物、其互变异构体或其药学上可接受的盐:
其中,
R1、R2、R3、R5分别独立地选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基;
当R2为OH时,R1和R3不同时选自H;
任选地,R2、R3可连接在一起形成一个3~6元环;
环A选自任选被1、2、3、4或5个R取代的5~6元杂芳环;
L选自:单键、-C(=O)、-C(=O)S-、-C(=O)N(RL)S(=O)2(C(RL)2)0-2-、-C(=O)N(C(RL)3)S(=O)2-、-N(RL)C(=O)O(C(RL)2)0-2-、-N(RL)C(=O)N(RL)(C(RL)2)0-2-、-OC(=O)N(RL)-、-OS(=O)2N(RL)-、-N(RL)C(=S)N(RL)-、-N(RL)C(=S)-、-P(=O)(ORL)O-、-S(=O)2N(RL)-;
RL选自H,或选自任选被1、2、或3个R取代的C1-3烷基;
R4选自H、或选自任选被1、2、3、4、或5个R取代的:C1-3烷基、C3-10环烷基、3~6元杂环烷基、5~6元芳基或5~6元杂芳基;
R分别独立地选自卤素、CN、OH、NH2、SH、或任选被1、2、3、4、或5个R’取代的:C1-3烷基、C1-3杂烷基;和/或
任选地,任何一个RL可与R4连接在一起形成一个任选被1、2、3、4、或5个R取代的4~6元环;
R’选自卤素、CN、OH、NH2、SH、Me、三氟甲基;
“杂”代表杂原子或杂原子团,选自-NH-、-O-、-S-、=O、=S、-C(=O)O-、-C(=O)-、-C(=S)-、-S(=O)-和/或-S(=O)2-;
每个上述含“杂”的基团上所述“杂”的数目为1、2、3、4、或5个。
本申请另一方面提供式Ⅴ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐:
其中,
R4选自H、或选自任选被1、2、3、4或5个R取代的C1-3烷基、C3-10环烷基、3~6元杂环烷基、5~6元芳基或5~6元杂芳基;
R5选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基;
R6选自H或OH;
n选自0、1或2;
L选自:单键、-C(=O)-、-C(=O)S-、-C(=O)N(RL)S(=O)2(C(RL)2)0-2-、-C(=O)N(C(RL)3)S(=O)2-、-N(RL)C(=O)O(C(RL)2)0-2-、-N(RL)C(=O)N(RL)(C(RL)2)0-2-、-OC(=O)N(RL)-、-OS(=O)2N(RL)-、-N(RL)C(=S)N(RL)-、-N(RL)C(=S)-、-P(=O)(OEt)O-、-S(=O)2N(RL)-、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(RL)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(ORL)O-;
上述RL选自H,或选自任选被1、2、或3个R取代的C1-3烷基;
上述R分别独立地选自卤素、CN、OH、NH2、SH,或任选被1、2、3、4或5个R’取代的:C1-3烷基、C1-3杂烷基和/或
任选地,任何一个RL与R4连接在一起形成一个任选被1、2、3、4、或5个R取代的4~6元环;
上述R’选自卤素、CN、OH、NH2、SH、Me或三氟甲基;
条件是,当R4选自C1-3烷基时,R不选自OH和NH2。
本申请的另一方面提供一种药物组合物,其包含治疗有效量的如式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示的化合物,其互变异构体、其立体异构体或其药学上可接受的盐,以及一种或多种药学上可接受的载体或赋形剂。
本申请另一方面提供如式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示的化合物,其互变异构体、其立体异构体或其药学上可接受的盐或者上述药物组合物在制备预防或治疗受益于FXR激动的疾病的用途,所述受益于FXR激动的疾病,包括心血管疾病、肝/胆系统疾病、肥胖症、糖尿病、下尿路症状(附近地区)与良性前列腺增生(BPH)或输尿管结石。
本申请的另一方面提供用于预防或治疗受益于FXR激动的疾病的方法,包括给予患者治疗有效量的如式Ⅰ所示的化合物,其互变异构体、其立体异构体或其药学上可接受的盐或者上述药物组合物,所述受益于FXR激动的疾病,包括心血管疾病、肝/胆系统疾病、肥胖症、糖尿病、下尿路症状(附近地区)与良性前列腺增生(BPH)或输尿管结石。
发明详述
本申请的一方面提供式Ⅰ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐:
其中,
R7、R8和R9分别独立地选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基,任选地,R8和R9可连接在一起形成一个3~6元环;或者,R9选自H,R7和R8与所连碳原子形成任选被1、2、3、4或5个R取代的5~6元杂芳环或C3-6环烷基;
上述R分别独立地选自卤素、CN、OH、NH2、SH,或任选被1、2、3、4或5个R’取代的C1-3烷基、C1-3杂烷基;
上述R’选自卤素、CN、OH、NH2、SH、Me或三氟甲基;
在一个方案中,在式Ⅰ所示化合物中,R9选自H,R7和R8与所连碳原子形成任选被1或2个R取代的咪唑基、吡唑基、吡咯基、噻吩基、恶唑基、噻唑基、呋喃基或环丙基。
本申请的另一方面提供式Ⅱ、式III或式IV所示化合物、其互变异构体或其药学上可接受的盐:
其中,
R1、R2、R3、R5分别独立地选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基;
当R2为OH时,R1和R3不同时选自H;
任选地,R2、R3可连接在一起形成一个3~6元环;
环A选自任选被1、2、3、4或5个R取代的5~6元杂芳环;
L选自:单键、-C(=O)、-C(=O)S-、-C(=O)N(RL)S(=O)2(C(RL)2)0-2-、-C(=O)N(C(RL)3)S(=O)2-、-N(RL)C(=O)O(C(RL)2)0-2-、-N(RL)C(=O)N(RL)(C(RL)2)0-2-、-OC(=O)N(RL)-、-OS(=O)2N(RL)-、-N(RL)C(=S)N(RL)-、-N(RL)C(=S)-、-P(=O)(ORL)O-、-S(=O)2N(RL)-;
RL选自H,或选自任选被1、2、或3个R取代的C1-3烷基;
R4选自H、或选自任选被1、2、3、4、或5个R取代的:C1-3烷基、C3-10环烷基、3~6元杂环烷基、5~6元芳基或5~6元杂芳基;
R分别独立地选自卤素、CN、OH、NH2、SH、或任选被1、2、3、4、或5个R’取代的:C1-3烷基、C1-3杂烷基;和/或
任选地,任何一个RL可与R4连接在一起形成一个任选被1、2、3、4、或5个R取代的4~6元环;
R’选自卤素、CN、OH、NH2、SH、Me、三氟甲基;
“杂”代表杂原子或杂原子团,选自-NH-、-O-、-S-、=O、=S、-C(=O)O-、-C(=O)-、-C(=S)-、-S(=O)-和/或-S(=O)2-;
每个上述含“杂”的基团上所述“杂”的数目为1、2、3、4、或5个。
本发明的一个方案中,上述R选自卤素、CN、OH、NH2、SH、或任选被1、2、3、4、或5个R’取代的:C1-3烷基、C1-3烷氧基、C1-3烷氨基。
本发明的一个方案中,上述R2、R3连接在一起形成一个环丙基。
本发明的一个方案中,上述环A选自任选被1或2个R取代的咪唑基、吡唑基、吡咯基、噻吩基、恶唑基、噻唑基、呋喃基。
本发明的一个方案中,上述L选自:单键、-C(=O)、-C(=O)S-、-C(=O)NHS(=O)2(CH2)0-2-、-C(=O)N(CH3)S(=O)2-、-NHC(=O)O(CH2)0-2-、-NHC(=O)N(RL)(CH2)0-2-、-OC(=O)NH-、-OS(=O)2NH-、-NHC(=S)NH-、-NHC(=S)-、-P(=O)(ORL)O-、-S(=O)2NH-。
本发明的一个方案中,上述L选自:单键、-C(=O)、-C(=O)S-、-C(=O)NHS(=O)2-、-C(=O)NHS(=O)2CH2-、-C(=O)NHS(=O)2(CH2)2-、-C(=O)N(CH3)S(=O)2-、-NHC(=O)O(CH2)0-2-、-NHC(=O)O-、-NHC(=O)OCH2-、-NHC(=O)O(CH2)2-、-NHC(=O)NH-、-NHC(=O)NHCH2-、-NHC(=O)NH(CH2)2-、-OC(=O)NH-、-OS(=O)2NH-、-NHC(=S)NH-、-NHC(=S)-、-P(=O)(OEt)O-、-S(=O)2NH-。
本发明的一个方案中,上述结构单元-L-R4选自:
本申请的另一方面提供式Ⅴ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐:
其中,
R4选自H、或选自任选被1、2、3、4或5个R取代的C1-3烷基、C3-10环烷基、3~6元杂环烷基、5~6元芳基或5~6元杂芳基;
R5选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基;
R6选自H或OH;
n选自0、1或2;
L选自:单键、-C(=O)-、-C(=O)S-、-C(=O)N(RL)S(=O)2(C(RL)2)0-2-、-C(=O)N(C(RL)3)S(=O)2-、-N(RL)C(=O)O(C(RL)2)0-2-、-N(RL)C(=O)N(RL)(C(RL)2)0-2-、-OC(=O)N(RL)-、-OS(=O)2N(RL)-、-N(RL)C(=S)N(RL)-、-N(RL)C(=S)-、-P(=O)(OEt)O-、-S(=O)2N(RL)-、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(RL)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(ORL)O-;
上述RL选自H,或选自任选被1、2、或3个R取代的C1-3烷基,优选RL选自H或C1-3烷基;
上述R分别独立地选自卤素、CN、OH、NH2、SH,或任选被1、2、3、4或5个R’取代的:C1-3烷基、C1-3杂烷基和/或
任选地,任何一个RL与R4连接在一起形成一个任选被1、2、3、4、或5个R取代的4~6元环;
上述R’选自卤素、CN、OH、NH2、SH、Me或三氟甲基;
条件是,当R4选自C1-3烷基时,R不选自OH和NH2。
在一个方案中,所述式Ⅴ所示化合物的立体异构体如下式Ⅴ’所示:
在一个方案中,在式Ⅴ所示化合物中,上述R选自卤素、CN、OH、NH2、SH,或任选被1、2、3、4或5个R’取代的C1-3烷基、C1-3烷氧基或C1-3烷氨基。
在一个方案中,在式Ⅴ所示化合物中,R5选自H、Me或Et。
在一个方案中,在式Ⅴ所示化合物中,上述L选自单键、-C(=O)-、-C(=O)S-、-C(=O)NHS(=O)2(CH2)0-2-、-C(=O)N(CH3)S(=O)2-、-NHC(=O)O(CH2)0-2-、-NHC(=O)N(RL)(CH2)0-2-、-OC(=O)NH-、-OS(=O)2NH-、-NHC(=S)NH-、-NHC(=S)-、-P(=O)(OEt)O-、-S(=O)2NH-、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(RL)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(ORL)O-。
在一个方案中,在式Ⅴ所示化合物中,上述L优选自单键、-C(=O)-、-C(=O)S-、-C(=O)NHS(=O)2-、-C(=O)NHS(=O)2CH2-、-C(=O)NHS(=O)2(CH2)2-、-C(=O)N(CH3)S(=O)2-、-NHC(=O)O-、-NHC(=O)OCH2-、-NHC(=O)O(CH2)2-、-NHC(=O)NH-、-NHC(=O)NHCH2-、-NHC(=O)NH(CH2)2-、-OC(=O)NH-、-OS(=O)2NH-、-NHC(=S)NH-、-NHC(=S)-、-P(=O)(OEt)O-、-S(=O)2NH-、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(CH3)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(OMe)O-。
在一个方案中,在式Ⅴ所示化合物中,上述结构单元-L-R4选自:
如下所述化合物:
药物组合物
本申请另一方面提供一种药物组合物,其包含治疗有效量的如式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示的化合物,其互变异构体、其立体异构体或其药学上可接受的盐,以及一种或多种药学上可接受的载体或赋形剂。
本申请的化合物或其盐可以作为活性物质单独给药,优选以其药物组合物的形式给药。
另一方面,本申请提供了药物组合物,其含有通式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示的化合物或其药学上可接受的盐、溶剂化物、多晶型、代谢物作为活性成分,以及一种或多种药学上可接受的载体。
本申请化合物或其药学上可接受的盐的给药可以以纯的形式或适宜的药物组合物的形式通过提供类似用途的药物的任何可接受的给药方式来进行。本申请的药物组合物可通过将本申请的化合物与适宜的药学上可接受的载体、稀释剂、介质或赋形剂相组合而制备。本申请的药物组合物可配制成固态、半固态、液态或气态制剂,如片剂、丸剂、胶囊剂、粉剂、颗粒剂、膏剂、乳剂、悬浮剂、溶液剂、栓剂、注射剂、吸入剂、凝胶剂、微球及气溶胶等等。
本申请的化合物或其药学上可接受的盐或其药物组合物的典型的给药途径包括但不限于口服、直肠、透黏膜、经肠给药,或者局部、经皮、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药等。优选的给药途径是口服给药。
本申请的药物组合物可以采用本领域普通技术人员所知悉的方法制造,如常规的混合法、溶解法、制粒法、制糖衣药丸法、磨细法、乳化法、冷冻干燥法等。
在优选的实施方案中,药物组合物是口服形式的。对于口服给药,可以通过将活性化合物与本领域熟知的药学上可接受的载体混合,来配制该药物组合物。这些载体能使本申请的化合物被配制成片剂、丸剂、锭剂、糖衣剂、胶囊剂、液体、凝胶剂、浆剂、悬浮剂等,用于对患者口服给药。
可以通过常规的混合、填充或压片方法来制备固体口服药物组合物。例如,可通过下述方法获得:将所述的活性化合物与固体赋形剂混合,任选地碾磨所得的混合物,如果需要则加入其它合适的辅料,然后将该混合物加工成颗粒,得到了片剂或糖衣剂的核心。适合的辅料包括但不限于:粘合剂、稀释剂、崩解剂、润滑剂、助流剂、甜味剂或矫味剂等。如微晶纤维素、葡萄糖溶液、阿拉伯胶浆、明胶溶液、蔗糖和淀粉糊;滑石、淀粉、硬脂酸镁、硬脂酸钙或硬脂酸;乳糖、蔗糖、淀粉、甘露糖醇、山梨糖醇或磷酸二钙;二氧化硅;交联羧甲基纤维素钠、预胶化淀粉、淀粉羟乙酸钠、藻酸、玉米淀粉、马铃薯淀粉、甲基纤维素、琼脂、羧甲基纤维素、交联聚乙烯吡咯烷酮等。可以根据通常药物实践中公知的方法任选地对糖衣剂的核心进行包衣,尤其使用肠溶包衣。
本申请的药物组合物还可适用于肠胃外给药,如合适的单位剂型的无菌溶液剂、混悬剂或冻干产品。能够使用适当的赋形剂,例如填充剂、缓冲剂或表面活性剂。
给予患者的化合物或组合物的量不固定,取决于给予的药物、给药的目的例如预防或治疗;患者的状态、给药的方式等。在治疗应用时,可给予已患疾病的患者足够治愈或至少部分抑制疾病及其并发症症状的量的组合物。有效剂量应取决于所治疗的疾病状态和主治临床医师的判断,该判断取决于例如疾病的严重程度、患者的年龄、体重和一般状况等因素。
给予患者的组合物可以是上述药用组合物形式。可通过常规灭菌技术或可过滤灭菌,将这些组合物灭菌。可将水溶液包装原样使用,或冻干,给药前,将冻干制剂与无菌水性载体混合。化合物制剂的pH通常为3~11,更优选5~9,最优选7~8。可以理解,使用某些前述赋形剂、载体或稳定剂会导致形成药物盐。
治疗用途
本申请的化合物是FXR激动剂。本申请的化合物可用于预防或治疗血脂代谢紊乱或与血脂代谢紊乱相关的疾病的方法,该方法包括对需要该治疗的患者施用治疗有效量的本申请的化合物。
本申请的化合物可用于降低总胆固醇水平,降低LDL胆固醇水平,降低VLDL胆固醇水平、提高HDL胆固醇水平,和/或降低甘油三酯水平。本申请所述的降低甘油三酯水平是指将需要治疗的对象中的甘油三酯降低到低于该预防或治疗对象在服用本申请化合物之前的最初的甘油三酯水平。例如,本申请化合物可以通过减少脂肪吸收,减少肝的甘油三酯产生或者减少肝的甘油三酯分泌。本申请化合物还可以降低血清甘油三脂和肝甘油三脂。
本申请的化合物可以用于预防或治疗受治疗者(例如哺乳动物,特别是人)中与高甘油三酯血和/或高胆固醇血有关的心血管疾病,例如但不仅限于动脉粥样硬化、动脉硬化症、高胆固醇血症、高血脂症、血栓形成、冠状动脉病、中风或高血压疾病。
本申请的化合物可以用于预防或治疗受治疗者(例如哺乳动物,特别是人)的肝/胆系统疾病,例如但不仅限于胆汁淤积性肝疾病、高HDL胆固醇疾病、高甘油三酯疾病或纤维变性疾病,具体例如但不仅限于非酒精性脂肪性肝炎(NASH)、原发性胆汁性肝硬化(PBC)、原发性硬化性胆管炎(PSC)、胆结石、非酒精性肝硬化、胆管闭锁、胆汁淤积性肝病、慢性肝病、肝炎感染(B型或C型)、酒精性肝病或肝纤维变性。
本申请的化合物可以用于预防或治疗受治疗者(例如哺乳动物,特别是人)的肥胖症。
本申请的化合物可以用于预防或治疗受治疗者(例如哺乳动物,特别是人)的糖尿病,或胰岛素抗性、葡萄糖不耐受相关的疾病。
本申请的化合物可以用于预防或治疗受治疗者(例如哺乳动物,特别是人)的下尿路症状(附近地区)与良性前列腺增生(BPH)或输尿管结石。
本申请另一方面提供如式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示的化合物,其互变异构体、其立体异构体或其药学上可接受的盐或者上述药物组合物在制备预防或治疗受益于FXR激动的疾病的用途,所述受益于FXR激动的疾病,包括心血管疾病、肝/胆系统疾病、肥胖症、糖尿病、下尿路症状(附近地区)与良性前列腺增生(BPH)或输尿管结石。
本申请的另一方面提供用于预防或治疗受益于FXR激动的疾病的方法,包括给予患者治疗有效量的如式Ⅰ、式Ⅱ、式III、式IV或式Ⅴ所示的化合物,其互变异构体、其立体异构体或其药学上可接受的盐或者上述药物组合物,所述受益于FXR激动的疾病,包括心血管疾病、肝/胆系统疾病、肥胖症、糖尿病、下尿路症状(附近地区)与良性前列腺增生(BPH)或输尿管结石。
所述心血管疾病包括与高甘油三酯血和/或高胆固醇血有关的心血管疾病。所述心血管疾病进一步包括动脉粥样硬化、动脉硬化症、高胆固醇血症、高血脂症、血栓形成、冠状动脉病、中风或高血压。所述肝/胆系统疾病包括胆汁淤积性肝疾病、高HDL胆固醇疾病、高甘油三酯疾病或纤维变性疾病。所述肝/胆系统疾病进一步包括非酒精性脂肪性肝炎(NASH)、原发性胆汁性肝硬化(PBC)、原发性硬化性胆管炎(PSC)、胆结石、非酒精性肝硬化、胆管闭锁、胆汁淤积性肝病、慢性肝病、肝炎感染(B型或C型)、酒精性肝病或肝纤维变性。
定义和说明
除非另有说明,本申请所用的下列术语和短语旨在具有下列含义。一个特定的术语或短语在没有特别定义的情况下不应该被认为是不确定的或不清楚的,而应该按照普通的含义去理解。当本文中出现商品名时,意在指代其对应的商品或其活性成分。在以下的说明中,包括某些具体的细节以对各个公开的实施方案提供全面的理解。然而,相关领域的技术人员会认识到,不采用一个或多个这些具体的细节,而采用其它方法、部件、材料等的情况下可实现实施方案。
除非本申请中另外要求,在说明书和权利要求书中,词语“包括(comprise)”及其英文变体例如“包括(comprises)”和“包括(comprising)”应解释为开放式的、含括式的意义,即“包括但不限于”。
在整个本说明书中提到的“一个方案”或“一实施方案”或“实施方案”或“在另一实施方案中”或“在某些实施方案中”意指在至少一实施方案中包括与该实施方案所述的相关的具体参考要素、结构或特征。因此,在整个说明书中不同位置出现的短语“一个方案”或“在一实施方案中”或“在实施方案中”或“在另一实施方案中”或“在某些实施方案中”不必全部指同一实施方案。此外,具体要素、结构或特征可以任何适当的方式在一个或多个实施方案中结合。
应当理解,在本申请说明书和附加的权利要求书中用到的单数形式的冠词“一”(对应于英文“a”、“an”和“the”)包括复数的对象,除非文中另外明确地规定。因此,例如提到的包括“催化剂”的反应包括一种催化剂,或两种或多种催化剂。还应当理解,术语“或”通常以其包括“和/或”的含义而使用,除非文中另外明确地规定。
术语“任选”或“任选地”是指随后描述的事件或情况可能发生或可能不发生,该描述包括发生所述事件或情况和不发生所述事件或情况。例如,乙基“任选”被卤素取代,指乙基可以是未被取代的(CH2CH3)、单取代的(如CH2CH2F)、多取代的(如CHFCH2F、CH2CHF2等)或完全被取代的(CF2CF3)。本领域技术人员可理解,对于包含一个或多个取代基的任何基团,不会引入任何在空间上不可能存在和/或不能合成的取代或取代模式。
本文所用的Cm~n指该部分中具有m~n个碳原子。例如,“C1-3烷基”指该烷基具有1~3个碳原子。
本文中的数字范围,是指给定范围中的各个整数。例如“C1-3烷基”指该基团可选自C1、C2和C3的烷基;“C3-10环烷基”指该基团可选自C3、C4、C5、C6、C7、C8、C9和C10的环烷基;“3~6元杂环烷基”指该基团可选自3元、4元、5元和6元的杂环烷基。
术语“取代”或“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代,包括重氢和氢的变体,只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为酮基(即=O)时,意味着两个氢原子被取代。酮取代不会发生在芳香基上。术语“任选被取代的”是指可以被取代,也可以不被取代,除非另有规定,取代基的种类和数目在化学上可以实现的基础上可以是任意的。
当任何变量(例如R)在化合物的组成或结构中出现一次以上时,其在每一种情况下的定义都是独立的。因此,例如,如果一个基团被0-2个R所取代,则所述基团可以任选地至多被两个R所取代,并且每种情况下的R都有独立的选项。此外,取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
当其中一个变量选自单键时,表示其连接的两个基团直接相连,比如“A-L-Z”中L代表单键时,表示该结构A与Z直接相连,实际上是A-Z。
当一个取代基的键可以交叉连接到一个环上的两个原子时,这种取代基可以与这个环上的任意原子相键合。当所列举的取代基中没有指明其通过哪一个原子连接到化学结构通式中包括但未具体提及的化合物时,这种取代基可以通过其任何原子相键合。取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。例如,结构单元表示其可在环己基或者环基二烯上的任意一个位置发生取代,包括
在本申请的部分优选方式中,所述L基团的右端与R4相连。例如,L可以选自-C(=O)S-,在本申请的部分优选方式中,-C(=O)S-的右端与R4相连,即S原子与R4相连;又例如,L可以选自-OC(=O)N(RL)-,在本申请的部分优选方式中,-OC(=O)N(RL)-的右端与R4相连,即N原子与R4相连;又例如,L可以选自-N(RL)C(=O)N(RL)(C(RL)2)0-2-,在本申请的部分优选方式中,-N(RL)C(=O)N(RL)(C(RL)2)0-2-的右端与R4相连,即“C(=O)N(RL)(C(RL)2)0-2”部分中的N原子与R4相连。
除非另有规定,术语“卤代素”或“卤素”本身或作为另一取代基的一部分表示氟、氯、溴或碘原子。
术语“烷基”是指由碳原子和氢原子组成的直链或支链的饱和的脂肪烃基团,其通过单键与分子的其余部分连接。该术语的非限制性实例包括甲基、乙基、丙基、丁基、戊基、己基、庚基、辛基、壬基、癸基、-CH(CH3)2、-CH(CH3)(CH2CH3)、-CH(CH2CH3)2、-C(CH3)3、-C(CH2CH3)3、-CH2CH(CH3)2、-CH2CH(CH3)(CH2CH3)等。术语“C1~8烷基”指具有1~8个碳原子的烷基。术语“C1~6烷基”指具有1~6个碳原子的烷基。术语“C1~4烷基”指具有1~4个碳原子的烷基。所述“烷基”、“C1~8烷基”、“C1~6烷基”或“C1~4烷基”可以是非取代的或是被一个或多个选自羟基、卤素或氨基的取代基取代。
本文所用的术语“环烷基”是指仅由碳原子和氢原子组成的全碳的环状饱和烃基团,包括单环结构、稠和并环结构、螺环结构或桥环结构,例如C3-10环烷基包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基、金刚烷基等。所述“环烷基”可以是未取代的或被一个或多个取代基独立地取代,所述的取代基包括但不限于烷基、烷氧基、氰基、羟基、芳基、杂芳基、氨基、卤素、磺酰基、亚磺酰基、磷酰基或羟基。
术语“芳基”是指具有共轭的π电子体系的全碳单环或稠合多环的芳香环基团。例如,芳基可以具有6-20个碳原子,6-14个碳原子或6-12个碳原子。“芳基”包括但不限于苯基、萘基和蒽基等。
术语“杂”表示杂原子或杂原子团(即含有杂原子的原子团),包括碳(C)和氢(H)以外的原子以及含有这些杂原子的原子团,例如包括氧(O)、氮(N)、硫(S)、硅(Si)、锗(Ge)、铝(Al)、硼(B)、-O-、-S-、=O、=S、-C(=O)O-、-C(=O)-、-C(=S)-、-S(=O)、-S(=O)2-,以及任选被被取代的-C(=O)N(H)-、-N(H)-、-C(=NH)-、-S(=O)2N(H)-或-S(=O)N(H)-;每个上述含“杂”的基团上所述“杂”的数目可选地为1、2、3、4或5个。
术语“杂烷基”是指由碳原子和氢原子组成的直链或支链的饱和的脂肪烃基团中,部分碳原子和氢原子被上述杂原子或杂原子团取代或替代。在一些实施例中,术语“杂烷基”本身或者与另一术语联合表示稳定的直链的、支链的烃原子团或其组合物,有一定数目的碳原子和至少一个杂原子组成。在一个典型实施例中,杂原子选自B、O、N和S,其中氮和硫原子任选地被氧化,氮杂原子任选地被季铵化。杂原子或杂原子团可以位于或杂烷基的任何内部位置(包括该烃基附着于分子其余部分的位置)。除非另有规定,术语“杂烷基”包括“烷氧基”、“烷氨基”和“烷硫基”。“杂烷基”的实例包括但不限于-CH2-CH2-O-CH3、-CH2-CH2-NH-CH3、-CH2-CH2-N(CH3)-CH3、-CH2-S-CH2-CH3、-CH2-CH2、-S(O)-CH3、-CH2-CH2-S(O)2-CH3、-CH=CH-O-CH3、-CH2-CH=N-OCH3和–CH=CH-N(CH3)-CH3、-OCH3、-OCH2CH3、-OCH2CH2CH3、-OCH(CH3)2、-NHCH3、-NHCH2CH3、-NHCH2CH2CH3、-NHCH(CH3)2、-SCH3、-SCH2CH3、-SCH2CH2CH3、-SCH(CH3)2。至多两个杂原子可以是连续的,例如-CH2-NH-OCH3。
术语“杂芳基”是指单环或稠合多环体系,其中含有至少一个选自上述杂原子或杂原子团的环原子结构,其余环原子为C,并且具有至少一个芳香环。优选地,所述杂芳基包括至少一个选自N、O、S的环原子。杂芳基的包括但不限于吡咯基、呋喃基、噻吩基、咪唑基、噁唑基、异噁唑基、1,2,4-噁二唑基、吡唑基、吡啶基、嘧啶基、吡嗪基、喹啉基、异喹啉基、四唑基、三唑基、三嗪基、苯并呋喃基、苯并噻吩基、吲哚基、异吲哚基等。术语“5元或6元杂芳基”是指具有5~6个环原子的杂芳基。所述“杂芳基”或“5元或6元杂芳基”可以是非取代的或是被一个或多个选自羟基、卤素或C1~4烷基的取代基取代。
术语“杂环烷基”是指无芳香性的单环、稠合多环、桥环或螺环体系基团,其中含有至少一个选自上述杂原子或杂原子团的环原子结构,其余环原子为C。优选地,所述“杂环烷基”包括至少一个子选自N、O、S、S(O)n(其中n为0、1或2)的杂原子作为环原子结构,其余环原子为C。这样的环可以是饱和的或不饱和的(例如具有一个或多个双键),但是不具有完全共轭的π-电子体系。“杂环烷基”的非限制性实例包括环氧乙烷基、环硫乙烷基、环氮乙烷基、吖丁啶基、噁丁环基、噻丁环基、四氢呋喃基、吡咯烷基、噁唑烷基、四氢吡唑基、吡咯啉基、二氢呋喃基、二氢噻吩基、哌啶基、四氢吡喃基、四氢噻喃基、吗啉基、哌嗪基、二氢吡啶基、四氢吡啶基、二氢吡喃基、四氢吡喃基、二氢噻喃基、氮杂环庚烷基、氧杂环庚烷基、硫杂环庚烷基、氧杂氮杂双环[2.2.1]庚基和氮杂螺[3.3]庚基、 等。术语“5元或6元杂环烷基”是指具有5~6个环原子的杂环烷基。
除非另有规定,“环”表示环烷基、杂环烷基、环烯基、杂环烯基、环炔基、杂环炔基、芳基或杂芳基。其中环烷基、杂环烷基、芳基或杂芳基如前文所定义。其中,环烯基或环炔基是指在环烷基的环原子结构中包括烯基或炔基结构。杂环烯基或杂环炔基是指在环烯基或环炔基中,其中含有至少一个选自上述杂原子或杂原子团的环原子结构,其余环原子为C。环烯基、杂环烯基、环炔基、杂环炔基是不饱和的(例如具有一个或多个双键),但是不具有完全共轭的π-电子体系。
这里所采用的术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
术语“药学上可接受的盐”是指本申请化合物的盐,由本申请发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本申请的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。当本申请的化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐,以及有机酸盐,还包括氨基酸(如精氨酸等)的盐,以及如葡糖醛酸等有机酸的盐(参见Berge et al.,"Pharmaceutical Salts",Journalof Pharmaceutical Science 66:1-19(1977))。本申请的某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。
优选地,以常规方式使盐与碱或酸接触,再分离母体化合物,由此再生化合物的中性形式。化合物的母体形式与其各种盐的形式的不同之处在于某些物理性质,例如在极性溶剂中的溶解度不同。
除了盐的形式,本申请所提供的化合物还存在前药形式。本文所描述的化合物的前药容易地在生理条件下发生化学变化从而转化成本申请的化合物。此外,前体药物可以在体内环境中通过化学或生化方法被转换到本申请的化合物。
本申请的某些化合物可以以非溶剂化形式或者溶剂化形式存在,包括水合物形式。一般而言,溶剂化形式与非溶剂化的形式相当,都包含在本申请的范围之内。
本申请的某些化合物可以具有不对称碳原子(光学中心)或双键。外消旋体、非对映异构体、几何异构体和单个的异构体都包括在本申请的范围之内。
本文中消旋体、ambiscalemic and scalemic或者对映体纯的化合物的图示法来自Maehr,J.Chem.Ed.1985,62:114-120。1985年,62:114-120。除非另有说明,用楔形键和虚线键表示一个立体中心的绝对构型。当本文所述化合物含有烯属双键或其它几何不对称中心,除非另有规定,它们包括E、Z几何异构体。同样地,所有的互变异构形式均包括在本申请的范围之内。
本申请的化合物可以存在特定的几何或立体异构体形式。本申请设想所有的这类化合物,包括顺式和反式异构体、(-)-和(+)-对对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体,及其外消旋混合物和其他混合物,例如对映异构体或非对映体富集的混合物,所有这些混合物都属于本申请的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物,均包括在本申请的范围之内。
可以通过的手性合成或手性试剂或者其他常规技术制备光学活性的(R)-和(S)-异构体以及D和L异构体。如果想得到本申请某化合物的一种对映体,可以通过不对称合成或者具有手性助剂的衍生作用来制备,其中将所得非对映体混合物分离,并且辅助基团裂开以提供纯的所需对映异构体。或者,当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时,与适当的光学活性的酸或碱形成非对映异构体的盐,然后通过本领域所公知的分步结晶法或色谱法进行非对映异构体拆分,然后回收得到纯的对映体。此外,对映异构体和非对映异构体的分离通常是通过使用色谱法完成的,所述色谱法采用手性固定相,并任选地与化学衍生法相结合(例如由胺生成氨基甲酸盐)。
本申请的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如,可用放射性同位素标记化合物,比如氚(3H),碘-125(125I)或C-14(14C)。本申请的化合物的所有同位素组成的变换,无论放射性与否,都包括在本申请的范围之内。
术语“药学上可接受的载体”是指能够递送本申请有效量活性物质、不干扰活性物质的生物活性并且对宿主或者患者无毒副作用的任何制剂或载体介质代表性的载体包括水、油、蔬菜和矿物质、膏基、洗剂基质、软膏基质等。这些基质包括悬浮剂、增粘剂、透皮促进剂等。它们的制剂为化妆品领域或局部药物领域的技术人员所周知。关于载体的其他信息,可以参考Remington:The Science and Practice of Pharmacy,21st Ed.,Lippincott,Williams&Wilkins(2005),该文献的内容通过引用的方式并入本文。
术语“赋形剂”通常是指配制有效的药物组合物所需要载体、稀释剂和/或介质。
针对药物或药理学活性剂而言,术语“有效量”或“治疗有效量”是指无毒的但能达到预期效果的药物或药剂的足够用量。对于本申请中的口服剂型,组合物中一种活性物质的“有效量”是指与该组合物中另一种活性物质联用时为了达到预期效果所需要的用量。有效量的确定因人而异,取决于受体的年龄和一般情况,也取决于具体的活性物质,个案中合适的有效量可以由本领域技术人员根据常规试验确定。
术语“活性成分”、“治疗剂”,“活性物质”或“活性剂”是指一种化学实体,它可以有效地治疗目标紊乱、疾病或病症。
术语“患者”是指包括哺乳动物在内的任何动物,优选小鼠、大鼠、其它啮齿类动物、兔、狗、猫、猪、牛、羊、马或灵长类动物,最优选人。
本文中使用的短语“治疗有效量”是指研究人员、兽医、医师或其它临床医师正在组织、系统、动物、个体或人中寻找的引起生物学或医学反应的活性化合物或药物的量,它包括以下一项或多项:
(1)预防疾病:例如在易感染疾病、紊乱或病症但尚未经历或出现疾病病理或症状的个体中预防疾病、紊乱或病症。
(2)抑制疾病:例如在正经历或出现疾病、紊乱或病症的病理或症状的个体中抑制疾病、紊乱或病症(即阻止病理和/或症状的进一步发展)。
(3)缓解疾病:例如在正经历或出现疾病、紊乱或病症的病理或症状的个体中缓解疾病、紊乱或病症(即逆转病理和/或症状)。
本申请化合物的治疗剂量可根据例如以下而定:治疗的具体用途、给予化合物的方式、患者的健康和状态,以及签处方医师的判断。本申请化合物在药用组合物中的比例或浓度可不固定,取决于多种因素,它们包括剂量、化学特性(例如疏水性)和给药途径。例如可通过含约0.1~10%w/v该化合物的生理缓冲水溶液提供本申请化合物,用于肠胃外给药。某些典型剂量范围为约1μg/kg~约1g/kg体重/日。在某些实施方案中,剂量范围为约0.01mg/kg~约100mg/kg体重/日。剂量很可能取决于此类变量,如疾病或病症的种类和发展程度、具体患者的一般健康状态、所选择的化合物的相对生物学效力、赋形剂制剂及其给药途径。可通过由体外或动物模型试验系统导出的剂量-反应曲线外推,得到有效剂量。
本申请的化合物可以通过本领域技术人员所熟知的多种合成方法来制备,包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式,优选的实施方式包括但不限于本申请的实施例。
本申请具体实施方式的化学反应是在合适的溶剂中完成的,所述的溶剂须适合于本申请的化学变化及其所需的试剂和物料。为了获得本申请的化合物,有时需要本领域技术人员在已有实施方式的基础上对合成步骤或者反应流程进行修改或选择。
本领域任何合成路线规划中的一个重要考量因素是为反应性官能团(如本申请中的氨基)选择合适的保护基。对于经过训练的从业者来说,Greene and Wuts的(ProtectiveGroups In Organic Synthesis,Wiley and Sons,1991)是这方面的权威。本申请引用的所有参考文献整体上并入本申请。
可按照本领域中已知的任何合适的方法,监测本文中所述反应。例如,可通过广谱方法例如核磁共振波谱(例如1H或13C)、红外光谱、分光光度测定(例如UV-可见光)或质谱,或通过色谱例如高效液相色谱(HPLC)或薄层层析监测产物形成。
本申请所使用的溶剂可经市售获得。本申请采用下述缩略词:aq代表水;HATU代表O-(7-氮杂苯并三唑-1-基)-N,N,N',N'-四甲基脲六氟磷酸盐;EDC代表N-(3-二甲基氨基丙基)-N'-乙基碳二亚胺盐酸盐;m-CPBA代表3-氯过氧苯甲酸;eq代表当量、等量;CDI代表羰基二咪唑;DCM代表二氯甲烷;PE代表石油醚;DIAD代表偶氮二羧酸二异丙酯;DMF代表N,N-二甲基甲酰胺;DMSO代表二甲亚砜;EtOAc代表乙酸乙酯;EtOH代表乙醇;MeOH代表甲醇;CBz代表苄氧羰基,是一种胺保护基团;BOC代表叔丁基羰基,是一种胺保护基团;HOAc代表乙酸;NaCNBH3代表氰基硼氢化钠;r.t.代表室温;O/N代表过夜;THF代表四氢呋喃;Boc2O代表二-叔丁基二碳酸酯;TFA代表三氟乙酸;TFAA代表三氟乙酸酐;DIPEA代表二异丙基乙基胺;SOCl2代表氯化亚砜;CS2代表二硫化碳;TsOH代表对甲苯磺酸;NFSI代表N-氟-N-(苯磺酰基)苯磺酰胺;NCS代表1-氯吡咯烷-2,5-二酮;n-Bu4NF代表氟化四丁基铵;iPrOH代表2-丙醇;mp代表熔点;LDA代表二异丙基胺基锂;PTSA代表对甲基苯磺酸;TMSCl代表三甲基氯硅烷;BF3-Et2O代表三氟化硼乙醚;Ac2O代表醋酸酐;DMAP代表N,N-二甲基氨基吡啶;EDCI代表1-乙基-3-(3-二甲氨基丙基)碳二亚胺盐酸盐;TEA代表三乙胺;TBTU代表O,N-二甲基羟基胺盐酸盐;MeMgBr代表甲基溴化镁;Burgess reagent代表伯吉斯试剂;Bu2OSn代表氧化二丁基锡;TMSN3代表三甲基硅基叠氮;DHP代表3,4-二氢吡喃;PCC代表吡啶铬酸盐;AcCl代表乙酰氯;TMSCF3代表三甲基三氟甲基硅醚;TBAF代表四丁基氟化铵;Pb(OAc)4代表四乙酸铅;P(OEt)3代表三乙基亚磷酸酯;Pyridine代表吡啶;PPh3代表三苯基磷;Thiophosgene代表硫光气;DAST代表二乙胺基三氟化硫;Et2Zn代表二乙基锌;Ph3PCH2OCH3Cl代表甲氧甲基三苯基氯化磷;n-BuLi代表正丁基锂;PhSO2Cl代表苯基磺酰氯;MsCl代表甲烷磺酰氯;TMSNCO代表三甲基硅基异氰酸酯。
具体实施方式
为了更详细地说明本发明,给出下列实例,但本发明的范围并非限定于此。
参考例1 INT-747的制备
参考例1A
向鹅去氧胆酸(60.0克,152.8毫摩尔)的甲醇/醋酸/水/乙酸乙酯(360/120/30/780毫升)溶液中分批加入四丁基溴化铵(81.0克,251.3毫摩尔)和溴化钠(9.0克,87.5毫摩尔),再在0摄氏度下于30分钟内滴加次氯酸钠(210毫升,3.4摩尔),在28摄氏度下搅拌16小时后,加入饱和的亚硫酸氢钠溶液(500毫升)淬灭,水层用乙酸乙酯(1000毫升×2)萃取,将合并的有机层再用水(1000毫升×5)洗涤,将有机层用硫酸钠干燥,过滤并旋干,残余物通过重结晶(二氯甲烷,200毫升)得到参考例1A(黄色固体,41.0克,69.0%产率)。1H NMR(400MHz,METHANOL-d4)δ3.44-3.60(m,1H),2.99(dd,J=5.77,12.30Hz,1H),2.54(t,J=11.29Hz,1H),2.08-2.41(m,3H),2.00-2.08(m,1H),1.75-1.96(m,6H),1.28-1.69(m,9H),1.09-1.27(m,8H),0.97(d,J=6.53Hz,3H),0.71(s,3H).
参考例1B
向参考例1A化合物(246.0克,629.9毫摩尔)的甲醇(2升)溶液中一次性加入对甲苯磺酸(10.9克,63.0毫摩尔),在80摄氏度反应4小时。冷却至室温后,蒸干,用饱和碳酸氢钠溶液(1500毫升)淬灭后,水层用乙酸乙酯(1500毫升×3)萃取,合并的有机层用盐水(1000毫升×3)洗涤后,经硫酸钠干燥,过滤并旋干,残余物通过重结晶(乙酸乙酯,500毫升)得到参考例1B(白色固体,202克,79%产率)。1H NMR(400MHz,CHLOROFORM-d)δ3.66(s,3H),3.55-3.62(m,1H),2.85(dd,J=6.02,12.55Hz,1H),2.28-2.43(m,2H),2.13-2.26(m,2H),1.64-2.04(m,10H),1.19-1.51(m,11H),1.00-1.17(m,3H),0.86-0.97(m,3H),0.65(s,3H).
参考例1C
零下78摄氏度,氮气保护下,向三甲基氯硅烷(107.5克,989.5毫摩尔)的四氢呋喃(500.0毫升)溶液中滴加二异丙基氨基锂(87.4克,815.6毫摩尔),搅拌40分钟后,再滴加参考例1B化合物(50克,123.6毫摩尔)的四氢呋喃(300毫升)溶液。滴加完毕后在零下78摄氏度下继续搅拌40分钟,再加入三乙胺(182.5克,1.8摩尔),1小时后,用饱和碳酸氢钠(1000毫升)淬灭,水层用乙酸乙酯(1000毫升×3)萃取。将合并的有机层再用水(100毫升×6)和饱和食盐水(1000毫升×2)洗,将有机层用硫酸钠干燥,过滤并旋干,得到参考例1C(棕黄色油状物,68克,收率100%)可直接用于下一步而无需进一步纯化。1H NMR(400MHz,CHLOROFORM-d)δ4.75(dd,J=1.38,5.90Hz,1H),3.69(s,3H),3.48-3.59(m,1H),2.13-2.42(m,2H),1.52-2.04(m,10H),1.29-1.48(m,7H),0.99-1.23(m,5H),0.95(d,J=6.53Hz,3H),0.85(s,3H),0.70(s,3H),0.17-0.20(m,9H),0.13(s,9H).
参考例1D
向参考例1C化合物(68.0克,123.9毫摩尔)的二氯甲烷(500.0毫升)溶液中加入无水乙醛(10.1克,229.2毫摩尔)。零下78摄氏度氮气保护下逐滴加入三氟化硼-乙醚(64.4克,453.4毫摩尔)的二氯甲烷(300毫升)溶液。滴加速度需保持内温为零下78摄氏度,搅拌1小时后,升温至30摄氏度继续搅拌2小时,将上述溶液用饱和碳酸氢钠(1000毫升)淬灭,水层用二氯甲烷(1000毫升×3)萃取,合并的有机层用饱和食盐水(1000毫升×2)洗涤,硫酸钠干燥,过滤并旋干,残余物通过柱色谱纯化得到参考例1D(黄色固体,43.0克,收率81.0%)。1H NMR(400MHz,CHLOROFORM-d)δ6.12(q,J=7.03Hz,1H),3.52-3.66(m,4H),2.54(dd,J=4.02,13.05Hz,1H),2.13-2.40(m,5H),1.68-1.98(m,7H),1.65(d,J=7.03Hz,3H),1.00-1.52(m,11H),0.97(s,3H),0.89(d,J=6.53Hz,3H),0.61(s,3H).
参考例1E
向参考例1D化合物(212.0克,492.3毫摩尔)的甲醇(500.0毫升)溶液中加入NaOH(39.4克,984.6毫摩尔)的水(50.0毫升)溶液,50摄氏度下搅拌2小时。旋干溶剂后,加水(500.0毫升),用乙酸乙酯(500.0毫升×2)萃取,水相用稀HCl调至pH至3,再用二氯甲烷(600.0毫升×2)萃取,将合并的有机层浓缩,残余物通过重结晶(乙醇,200.0毫升)纯化得到参考例1E(黄色固体,147.0克,收率72.0%)。1H NMR(400MHz,CHLOROFORM-d)δ6.19(q,J=7.36Hz,1H),3.60-3.74(m,1H),2.58(dd,J=4.02,13.05Hz,1H),2.40(tt,J=5.02,10.29Hz,3H),2.19-2.32(m,2H),1.61-2.06(m,10H),1.04-1.54(m,14H),1.01(s,3H),0.95(d,J=6.53Hz,3H),0.65(s,3H).
参考例1F
向参考例1E化合物(140.0克,336.1毫摩尔)的NaOH(0.5摩尔)水溶液(600.0毫升)中一次性加入10%Pd-C(19.9克,134.4毫摩尔),通入15psi的氢气,在100摄氏度下反应16小时。抽滤,滤液用稀盐酸调pH至3,水层用二氯甲烷(1500.0毫升×3)萃取,合并的有机层用盐水(1000.0毫升×3)洗涤后,经硫酸钠干燥,过滤并旋干,得到参考例1F(白色固体,101.0克,收率72.0%)可直接用于下一步而无需进一步纯化。1H NMR(400MHz,CHLOROFORM-d)δ3.49-3.60(m,1H),2.70(q,J=6.02Hz,1H),2.12-2.45(m,4H),1.65-2.02(m,9H),1.29-1.52(m,6H),1.05-1.24(m,8H),0.93(d,J=6.53Hz,5H),0.81(t,J=7.53Hz,3H),0.66(s,3H).
参考例1INT-747
向参考例1F化合物(16.0克,38.2毫摩尔)的氢氧化钠(2摩尔,100.0毫升)溶液中分批加入硼氢化钠(8.7克,229.3毫摩尔),在100摄氏度搅拌2小时。冷却至室温后加入饱和氯化铵水溶液(150.0毫升),用稀盐酸调pH至3,水层用二氯甲烷(300.0毫升×3)萃取,合并的有机层用盐水(200.0毫升×3)洗涤后,经硫酸钠干燥,过滤并蒸发,残余物通过柱色谱纯化得到参考例1(白色固体,14.5克,收率90.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.71(br.s,1H),3.36-3.48(m,1H),2.18-2.47(m,2H),1.56-2.01(m,10H),1.06-1.54(m,15H),0.86-0.97(m,9H),0.66(s,3H).
路线1
实施例1
实施例1A
氮气保护下,向参考例1化合物(1.0克,2.4毫摩尔)和N,N-二甲基氨基吡啶(30.0毫克,0.2毫摩尔)的吡啶溶液(10.0毫升)中加入乙酸酐(1.0克,9.5毫摩尔),在40摄氏度下搅拌12小时后,加入水(100.0毫升)淬灭,水层用乙酸乙酯(100.0毫升×2)萃取,有机层依次用1摩尔的盐酸水溶液和饱和食盐水洗涤,将合并的有机层用硫酸钠干燥,过滤并旋干,残余物通过柱色谱纯化得到实施例1A化合物(1.1克,92.0%产率)。
实施例1B
实施例1A化合物(0.1克,0.2毫摩尔)和羰基二咪唑(60.0毫克,0.4毫摩尔)的乙腈(3毫升)混合物在25摄氏度反应0.5小时,然后加入硫氢化钠(40.0毫克,0.8毫摩尔),25摄氏度下继续反应12小时。减压浓缩后用水(80.0毫升)稀释,稀盐酸调pH至3,水层用乙酸乙酯(100.0毫升×2)萃取,合并的有机层用水(100.0毫升)、盐水(100.0毫升)洗涤后,经硫酸钠干燥,过滤并旋干,残余物通过制备TLC板纯化得到标题实施例1B化合物(40.0毫克,收率39.0%)。1H NMR(400MHz,DMSO-d6)δ4.98(br.s.,1H),4.52-4.34(m,1H),2.38-2.13(m,2H),2.04-1.85(m,7H),1.84-1.49(m,9H),1.38(d,J=8.5Hz,5H),1.26-0.99(m,10H),0.95-0.71(m,9H),0.60(s,3H).
实施例1
氮气保护下,向实施例1B化合物(30.0毫克,0.06毫摩尔)的水(2.0毫升)和乙醇(2.0毫升)混合物中加入氢氧化钾(0.5克,8.9毫摩尔)。80摄氏度下搅拌24小时后,用1摩尔盐酸中和,水层用乙酸乙酯(100毫升×4)萃取。将合并的有机层用硫酸钠干燥,过滤并旋干,残余物通过制备TLC板纯化得到实施例1化合物(20.0毫克,收率62.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.70(br.s.,1H),3.48-3.35(m,1H),2.47-2.33(m,1H),2.30-2.17(m,1H),2.00-1.72(m,7H),1.70-1.55(m,3H),1.52-1.26(m,11H),1.22-1.10(m,3H),1.04-0.86(m,10H),0.65(s,3H).
路线2
实施例2
实施例2A
氮气保护下,向参考例1化合物(2.7克,6.4毫摩尔)和甲酸(0.3克,6.4毫摩尔)的四氢呋喃(40毫升)中加入高氯酸(6.0克,60.0毫摩尔)。55摄氏度下搅拌6小时后,减压浓缩后用水(100毫升)稀释,水层用乙酸乙酯(100毫升×2)萃取。将合并的有机层用硫酸钠干燥,过滤并旋干,残余物通过柱色谱纯化得到实施例2A化合物(2.8克,收率92.0%)。1H NMR(400MHz,CHLOROFORM-d)δ8.16(s,1H),8.05(s,1H),5.20(br.s.,1H),4.77-4.65(m,1H),2.45-2.34(m,1H),2.31-2.21(m,1H),2.01-1.58(m,11H),1.55-1.30(m,8H),1.22-1.05(m,6H),0.97-0.88(m,9H),0.66(s,3H).
实施例2B
氮气保护下向实施例2A化合物(100毫克,0.2毫摩尔)和甲基磺酰胺(18.0毫克)的二氯甲烷溶液(5.0毫升)中加入1-乙基-3-(3-二甲氨基丙基)碳二亚胺盐酸盐(44毫克,0.2毫摩尔)和N,N-二甲基氨基吡啶(3.8毫克,0.03毫摩尔),混合物在25摄氏度反应4小时。加入二氯甲烷(120毫升)稀释,用水洗涤,有机相用无水硫酸钠干燥后,真空干燥除去溶液,残余物通过柱色谱纯化得到实施例2B化合物(60.0毫克,收率54.0%)。1H NMR(400MHz,CHLOROFORM-d)δ8.52(s,1H),8.05-8.01(m,1H),4.75-4.62(m,1H),3.72(br.s.,1H),3.31(s,3H),2.43-2.34(m,1H),2.29-2.20(m,1H),1.99-1.62(m,10H),1.54-1.32(m,10H),1.23-1.03(m,5H),0.97-0.88(m,9H),0.66(s,3H).
实施例2
将实施例2B化合物(60.0毫克,0.1毫摩尔)和甲醇钠(6.0毫克,0.1毫摩尔)的甲醇(3毫升)溶液在25摄氏度下搅拌1小时,稀酸调pH=1,水相用乙酸乙酯(20毫升×3)萃取,有机相用无水硫酸钠干燥,真空除去溶剂,残余物通过制备型TLC板纯化得到实施例2化合物(20.0毫克,收率38.0%)。1H NMR(400MHz,CHLOROFORM-d)δ8.85(s,1H),3.71(br.s.,1H),3.47-3.39(m,1H),3.33-3.28(m,3H),2.43-2.33(m,1H),2.24(ddd,J=6.3,9.7,15.7Hz,1H),1.96(d,J=11.8Hz,1H),1.88-1.76(m,5H),1.72-1.57(m,5H),1.53-1.32(m,12H),1.22-1.13(m,3H),1.06-0.98(m,1H),0.97-0.88(m,9H),0.66(s,3H).
实施例3-至实施例26的制备参考实施例2的操作,通过路线2制备得到,所得结果如下:
路线3
实施例27
实施例3A
将参考例1F化合物(10.0克,23.9毫摩尔)溶于四氢呋喃(60.0毫升),加入高氯酸(240.0毫克,2.4毫摩尔,144.6微升)(大约10滴),于三十摄氏度下,半小时内逐滴加入甲酸(40.3克,874.7毫摩尔,33.0毫升),反应液于五十摄氏度搅拌十一点五小时。浓缩除去溶剂,向反应液中加入水(35.0毫升),乙酸乙酯萃取(30.0毫升×3)。有机层经水洗(10.0毫升×2),无水硫酸钠干燥,过滤和浓缩得到粗产物。粗产物经柱层析分离得到实施例3A化合物(7.0克,15.7毫摩尔,65.6%产率)。1H NMR(400MHz,CHLOROFORM-d)δ=8.01(s,1H),4.86-4.73(m,1H),2.82-2.67(m,1H),2.47-2.35(m,2H),2.33-2.16(m,2H),2.05-1.93(m,2H),1.89(d,J=13.1Hz,2H),1.82(dd,J=5.5,16.8Hz,2H),1.75(dd,J=6.5,14.1Hz,3H),1.71(br.s.,1H),1.58-1.30(m,7H),1.26(s,3H),1.23-1.02(m,4H),0.95(d,J=6.5Hz,3H),0.83(t,J=7.4Hz,3H),0.68(s,3H).
实施例3B
零摄氏度下将实施例3A化合物(5.8克,13.0毫摩尔)溶于三氟乙酸(40.0毫升)和三氟乙酸酐(20.5克,97.4毫摩尔),待固体溶解后,分批加入亚硝酸钠(2.7克,39.0毫摩尔),于零摄氏度继续搅拌一小时够,升温至四十摄氏度继续搅拌一小时。待反应液冷至三十摄氏度,在零摄氏度下,用零点五摩尔氢氧化钠水溶液中和(pH=7-8)。反应液用乙酸乙酯萃取(40毫升×3),有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩。粗产物经色谱柱(硅胶)分离得到实施例3B化合物(3.5克,8.5毫摩尔,93.0%产率)。1H NMR(400MHz,CHLOROFORM-d)δ=3.59-3.47(m,1H),2.69(q,J=6.2Hz,1H),2.42-2.31(m,2H),2.29-2.15(m,2H),2.01-1.88(m,2H),1.86-1.68(m,7H),1.61-1.45(m,6H),1.26(t,J=7.2Hz,5H),1.19-1.12(m,5H),1.02-0.91(m,1H),0.80(t,J=7.4Hz,3H),0.71-0.64(m,3H).
实施例3C
将实施例3B化合物(3.5克,8.5毫摩尔)溶于甲醇(100.0毫升),加入氢氧化钾水溶液(70.0克,1.3mol,溶于水100.0毫升),反应液于一百摄氏度搅拌十二小时。浓缩除去部分溶剂,二氯甲烷萃取(30毫升×3)。水相经一摩尔盐酸酸化(pH=3-4),用乙酸乙酯萃取(30毫升×3),有机层经水洗(20毫升),无水硫酸钠干燥,过滤和浓缩得到粗产物。无需纯化得到实施例3C化合物(3.2克,7.9毫摩尔,93.5%产率)。1H NMR(400MHz,CHLOROFORM-d)δ=3.65-3.50(m,1H),2.71(d,J=5.8Hz,1H),2.48(dd,J=2.6,14.9Hz,1H),2.43-2.31(m,2H),2.22-2.15(m,1H),2.07-1.98(m,2H),1.95-1.86(m,3H),1.82-1.70(m,6H),1.53-1.46(m,3H),1.19-1.10(m,6H),1.02(d,J=6.3Hz,3H),0.86(d,J=10.3Hz,5H),0.69(s,3H)。
实施例3D
向氢氧化钠水溶液(949.2毫克,23.7毫摩尔,溶于水10.00毫升)加入实施例3C化合物(3.2克,7.9毫摩尔),反应液加热到八十摄氏度,分批加入硼氢化钠(1.8克,47.5毫摩尔),反应液于一百摄氏度搅拌十二小时。逐滴加入甲醇(6毫升),浓缩除去部分溶剂,反应液用一摩尔盐酸酸化(pH=5-6),乙酸乙酯萃取(40毫升×3),有机层经水洗(20毫升),无水硫酸钠干燥,过滤和浓缩,粗产物无需分离得到实施例3D(3.1克,7.6毫摩尔,96.4%产率)。1HNMR(400MHz,CHLOROFORM-d)δ=3.70(br.s.,1H),3.46-3.36(m,1H),2.52-2.39(m,1H),2.02-1.88(m,3H),1.85-1.77(m,4H),1.71-1.59(m,3H),1.53-1.44(m,4H),1.41-1.37(m,1H),1.36-1.27(m,4H),1.24-1.13(m,4H),1.04(d,J=6.5Hz,3H),0.92-0.88(m,6H),0.73-0.69(m,3H)。
实施例27
将实施例3D化合物(1.3克,3.2毫摩尔)加入到二氯甲烷中(30.0毫升),在加入N,N-二甲基-4-氨基吡啶(78.2毫克,640.00微摩尔)和EDCI(736.1毫克,3.8毫摩尔),反应液于三十摄氏度搅拌十二小时。向反应液中加入二氯甲烷(50毫升),有机层经水洗(10毫升×2),无水硫酸钠干燥,过滤和浓缩。粗产物经柱层析分离得到实施例27化合物(660.0毫克,1.4毫摩尔,42.6%产率)。1H NMR(400MHz,CHLOROFORM-d)δ=8.81(br.s.,1H),3.71(br.s.,1H),3.48-3.38(m,1H),3.31(s,3H),2.48(d,J=12.3Hz,1H),2.06-1.94(m,3H),1.88-1.75(m,5H),1.70-1.58(m,5H),1.53-1.40(m,5H),1.35-1.17(m,7H),1.03(d,J=6.0Hz,3H),0.92-0.89(m,5H),0.74-0.67(m,3H).
实施例28至实施例36的制备参考实施例27的操作,通过路线3制备得到,所得结果如下:
路线4
实施例37至实施例39的制备参考实施例27的操作,以实施例3D化合物为原料,通过路线4发生酰化反应制备得到,所得结果如下:
路线5
操作同实施例27,以实施例3D为原料,进行酰化反应经纯化得到实施例40如下:
路线6
实施例50
实施例6A
向实施例2A化合物(300.0毫克,629.0微摩尔)的甲苯溶液(5.0毫升)中加入氯化亚砜(1.3克,11.0毫摩尔)在100摄氏度下反应2小时。然后将溶液旋转蒸发干并用10毫升四氢呋喃溶解后再次旋干。将所得产物溶于10毫升四氢呋喃中,在0~10摄氏度下向其加入叠氮钠(122.8毫克,1.9毫摩尔)的水溶液(5.0毫升),在10摄氏度下反应2小时后,用冰水(20毫升)淬灭反应,水层用乙酸乙酯(30毫升)萃取。将合并的有机层用硫酸钠干燥,过滤并旋干后得到红色油状产物大约300毫克,将其溶解于2毫升无水甲苯,取一半溶液加入(S)-3-羟基四氢呋喃(500.0毫克,5.7毫摩尔)并在100摄氏度下反应10小时。反应结束后蒸干溶剂,用水(20毫升)淬灭反应,水层用乙酸乙酯(20毫升)萃取。将合并的有机层用硫酸钠干燥,过滤并旋干。粗品用制备薄层色谱板分离(石油醚:乙酸乙酯=3:1),得到实施例6A化合物(150.0毫克,240.3微摩尔,收率80.1%,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ8.17(s,1H),8.06(s,1H),5.33-5.17(m,2H),4.79-4.54(m,2H),4.02-3.77(m,5H),2.25-2.12(m,1H),2.08-1.71(m,10H),1.68-1.61(m,1H),1.55-1.41(m,6H),1.37-1.07(m,12H),0.99-0.90(m,10H),0.68(s,3H).
实施例50
向实施例6A化合物(150.0毫克,267微摩尔)的四氢呋喃/水(5毫升/3毫升)溶液中加入一水合氢氧化锂(11.2毫克,267微摩尔)在40摄氏度下反应5小时。反应结束后,乙酸乙酯(15毫升)萃取,将合并的有机层用硫酸钠干燥,过滤并旋干得到的粗品用制备薄层色谱板分离(二氯甲烷:乙酸乙酯=1:1),得到实施例50化合物(49.0毫克,收率34.2%,纯度95%)。1H NMR(400MHz,CHLOROFORM-d)δ5.27(br.s.,1H),4.64(br.s.,1H),3.99-3.80(m,6H),3.75-3.65(m,1H),3.47-3.37(m,1H),3.33-3.02(m,2H),2.24-2.12(m,1H),2.08-1.65(m,10H),1.55-1.38(m,7H),1.37-1.13(m,10H),1.09-1.01(m,1H),0.98(d,J=6.3Hz,3H),0.95-0.87(m,6H),0.68(s,3H).
实施例41至实施例49的制备参考实施例50的操作,通过路线6制备得到,所得结果如下:
路线7
实施例53
实施例7A
向实施例2A化合物(300.0毫克,629.4微摩尔)的甲苯溶液(5.0毫升)中加入氯化亚砜(1.3克,11.0毫摩尔)在100摄氏度下反应2小时。然后将溶液旋干用10毫升四氢呋喃溶解并再次旋干。将所得产物溶于10毫升四氢呋喃中,在0~10摄氏度下向其加入叠氮钠(122.8毫克,1.9毫摩尔)的水溶液(5.0毫升)。在10摄氏度下反应2小时后,用冰水(20毫升)淬灭反应,水层用乙酸乙酯(30毫升)萃取。将合并的有机层用硫酸钠干燥,过滤并蒸发得到红色油状产物大约300毫克,将其溶解于2毫升无水甲苯,取一半溶液在100摄氏度加热1小时,然后旋干溶剂,将产物溶解于二氯甲烷/四氢呋喃(1毫升/1毫升)的混合溶液中分别加入(3S)-3-羟基吡咯(500.0毫克,4.1毫摩尔,盐酸盐)和三乙胺(453.9毫克,4.5毫摩尔),10摄氏度反应10小时。反应结束后,加水(30毫升)淬灭反应,乙酸乙酯(30毫升)萃取,将合并的有机层用硫酸钠干燥,过滤并旋干得到的粗品用柱层析分离(二氯甲烷:甲醇=20:1),得到实施例7A化合物(160.0毫克,收率86.2%,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ=8.16(s,1H),8.05(s,1H),5.20(br.s.,1H),4.78-4.67(m,1H),4.48(br.s.,1H),4.16(br.s.,1H),3.54-3.26(m,5H),3.18-3.06(m,1H),2.70(br.s.,1H),2.04-1.39(m,19H),1.24-1.04(m,7H),1.01-0.95(m,6H),0.91(t,J=7.4Hz,3H),0.70-0.62(m,3H).
实施例53
向实施例7A化合物(150.0毫克,267.5微摩尔)的四氢呋喃/水(5毫升/3毫升)溶液中加入一水合氢氧化锂(33.7毫克,802.5微摩尔),在40摄氏度下反应5小时。反应结束后,用乙酸乙酯(20毫升)萃取,将合并的有机层用硫酸钠干燥,过滤并旋干得到的粗品用制备薄层色谱板分离(二氯甲烷:甲烷=20:1),得到实施例53化合物(90.0毫克,收率34%,纯度95%)。1H NMR(400MHz,CHLOROFORM-d)δ5.47(s,1H),4.37(br.s.,1H),3.63(br.s.,1H),3.47-3.34(m,3H),3.28-2.98(m,3H),2.08-1.01(m,29H),1.00-0.83(m,10H),0.68(s,3H).
实施例51至实施例58的制备参实施例53的操作,通过路线7制备得到,所得结果如下:
路线8
实施例59
实施例8A
参考例1化合物(100.0毫克,0.2毫摩尔),三乙胺(48.0毫克,0.5毫摩尔)和O,N-二甲基羟基胺盐酸盐(23.0毫克,0.2毫摩尔)的乙腈(2毫升)混合物在25摄氏度搅拌0.5小时后,加入O-苯并三氮唑-N,N,N’,N’-四甲基脲四氟硼酸(95.0毫克,0.3毫摩尔)。将所得混合物在25摄氏度搅拌12小时。真空旋蒸除去溶剂后,残余物通过柱色谱纯化得到实施例8A化合物,(90.2毫克,收率82.1%)。1H NMR(400MHz,CHLOROFORM-d)δ=3.73-3.67(m,4H),3.45-3.36(m,1H),3.18(s,3H),2.51-2.40(m,1H),2.38-2.27(m,1H),2.00-1.89(m,2H),1.87-1.74(m,5H),1.71-1.56(m,5H),1.53-1.31(m,11H),1.23-1.14(m,3H),1.06-0.99(m,1H),0.96(d,J=6.3Hz,3H),0.93-0.88(m,6H),0.67(s,3H).
实施例59
向实施例8A化合物(100.0毫克,0.2毫摩尔)的四氢呋喃(5毫升)溶液在0摄氏度下加入甲基溴化镁(0.4毫升,1.1毫摩尔,3N)的乙醚溶液,并且在0摄氏度下继续搅拌30分钟,然后升至室温搅拌12小时,加入冰水淬灭反应然后用乙酸乙酯(60毫升×2)萃取,水洗后有机相用无水硫酸钠干燥,过滤,真空除去溶剂后,残余物通过制备型TLC纯化得到实施例59化合物(6.0毫克,收率66.0%)。1H NMR(400MHz,CHLOROFORM-d)δ=3.71(br.s.,1H),3.48-3.35(m,1H),2.51-2.41(m,1H),2.39-2.29(m,1H),2.14(s,3H),1.99-1.79(m,5H),1.76-1.56(m,5H),1.51-1.30(m,10H),1.22-1.11(m,3H),1.00(dt,J=3.3,14.2Hz,1H),0.94-0.87(m,9H),0.66(s,3H).
路线9
实施例60
实施例9A
丙二酸单甲酯钾盐(2.4克,15.1毫摩尔)和氯化镁(479.4毫克,5.0毫摩尔)的四氢呋喃溶液(20毫升)于60摄氏度搅拌3小时,冷却至20摄氏度;于实施例2A化合物(2.4克,5.0毫摩尔)的四氢呋喃溶液(8毫升)加入羰基二咪唑(816.5毫克,5.0毫摩尔)的四氢呋喃溶液(8毫升)并在25摄氏度下搅拌2小时;然后将此溶液加入的之前的反应液中并于35摄氏度下搅拌10小时。反应结束后,减压旋干四氢呋喃,用乙酸乙酯萃取(100毫升×3),将合并的有机层用饱和食盐水(10毫升)洗2次,有机相用无水硫酸钠干燥,过滤并蒸发,残余物通过硅胶柱层析分离(石油醚:乙酸乙酯=20:1)纯化得到实施例9A化合物(2.2g,4.1毫摩尔,81.9%收率)。1H NMR(400MHz,CHLOROFORM-d)δ=8.15(s,1H),8.04(s,1H),5.19(br.s.,1H),4.76-4.66(m,1H),3.76-3.72(m,3H),3.45(s,2H),2.61-2.40(m,2H),2.01-1.57(m,11H),1.53-1.36(m,6H),1.34-1.03(m,12H),0.99-0.94(m,3H),0.93-0.87(m,6H),0.65(s,3H).
实施例60
氯化氢(200.0毫克,375.4微摩尔)的甲醇(0.7毫升)溶液于零下30摄氏度下加入氢氧化钠(25.0毫克)的甲醇和水的混合溶剂中(5毫升/0.3毫升)。搅拌30分钟后,上述混合溶液于零下30摄氏度下加入到盐酸羟胺(52.2毫克,750.9微摩尔)和氢氧化钠(45毫克)的甲醇和水(0.6毫升/0.6毫升)的混合溶液中,继续搅拌1小时,加入36.5%的盐酸(0.6毫升)然后升温至80摄氏度搅拌10小时。反应液浓缩,用二氯甲烷萃取(10毫升×3),将合并的有机层用饱和食盐水(10毫升)洗2次,有机相用无水硫酸钠干燥,过滤并蒸发,残余物通过制备板(二氯甲烷:甲醇=10:1)纯化得到实施例60化合物(20.00毫克,43.5微摩尔,11.6%收率)。1H NMR(400MHz,CHLOROFORM-d)δppm 5.64(s,1H),3.71(br.s.,1H),3.47-3.36(m,1H),2.75-2.47(m,2H),2.01-1.57(m,11H),1.49-1.28(m,1H),1.54-1.27(m,12H),1.25-1.09(m,4H),1.05-0.80(m,11H),0.66(s,3H).
实施例61
20摄氏度氮气保护下,向实施例62化合物(23.0毫克,50.0微摩尔)和碳酸钾(13.8毫克,100.1微摩尔)的二甲基甲酰胺(2.0毫升)溶液加入碘甲烷(8.5毫克,60.0微摩尔,3.7微升),在20摄氏度下搅拌3小时后,加入水5毫升,用乙酸乙酯萃取(10毫升×3),将合并的有机层用饱和食盐水(10毫升)洗2次,有机相用无水硫酸钠干燥,过滤并蒸发,残余物通过制备板(乙酸乙酯:石油醚=10:1)纯化得到实施例61化合物(9.0毫克,34.2%产率)。1HNMR(400MHz,CHLOROFORM-d)δppm 0.66(s,3H)0.89-1.00(m,13H)1.17-1.54(m,28H)1.55-1.93(m,18H)2.47-2.75(m,2H)3.71(br.s.,1H)3.95(s,3H)5.59(s,1H).
路线10
实施例62
实施例10A
将实施例9A化合物(200.0毫克,365.8微摩尔)溶于乙醇(3毫升),在0摄氏度下,一分钟内滴加完一水合肼(23.8毫克,475.6微摩尔,溶于乙醇2毫升),滴毕,移除冰浴,反应液于25摄氏度搅拌四小时。浓缩除去溶剂,残留物经薄层色谱柱层析分离得到实施例10A化合物(90.0毫克,184.9微摩尔,50.6%产率)。1H NMR(400MHz,CHLOROFORM-d)δ=8.17(d,J=4.8Hz,2H),5.21(br.s.,1H),3.49(d,J=5.5Hz,1H),3.44-3.35(m,1H),3.33-3.22(m,1H),2.00(d,J=12.3Hz,1H),1.91-1.79(m,4H),1.77-1.69(m,4H),1.65-1.57(m,11H),1.55-1.48(m,3H),1.45(s,3H),1.29(br.s.,18H),1.20-1.12(m,6H),1.06-0.96(m,9H),0.71-0.63(m,3H).
实施例62
将实施例10A化合物(90.0毫克,184.9微摩尔)溶于四氢呋喃(1.0毫升),甲醇(1.0毫升)和水(1.0毫升)中,加入一水合氢氧化锂(77.6毫克,1.9毫摩尔),反应液于25摄氏度搅拌十二小时。反应液用1摩尔盐酸中和到pH=5-6,溶液用乙酸乙酯萃取(10毫升×3)。所得有机层经水洗(10毫升),无水硫酸钠干燥和浓缩。残留物经薄层色谱柱层析分离得到实施例62化合物(68.0毫克,148.3微摩尔,80.2%产率)。1H NMR(400MHz,METHANOL-d4)=5.50(s,1H),3.67(br.s.,1H),3.33(br.s.,1H),2.68-2.56(m,1H),2.50-2.39(m,1H),2.03(s,2H),1.95-1.72(m,8H),1.68-1.49(m,8H),1.47(s,2H),1.37-1.33(m,4H),1.27-1.19(m,5H),1.05-1.00(m,4H),0.93(br.s.,5H),0.90(br.s.,5H),0.70(s,3H).
路线11
实施例63
实施例11A
参考例1化合物(35.0克,83.2毫摩尔)以及对甲苯磺酸(1.4克,8.3毫摩尔)的甲醇(350毫升)混合物在80摄氏度下搅拌2小时。冷却过滤,旋干溶剂后,残余物通过硅胶色谱法纯化得到化合物11A,(30克,收率82%)。1H NMR(400MHz,CHLOROFORM-d)δ3.70(br.s.,1H),3.66(s,3H),3.46-3.34(m,1H),2.41-2.29(m,1H),2.27-2.14(m,1H),1.99-1.29(m,24H),1.21-1.09(m,3H),1.05-0.85(m,10H),0.72-0.60(m,3H).
实施例11B
向实施例11A化合物(200.0毫克,460.0微摩尔)的甲醇(10毫升)溶液中加水合肼(515.0毫克,10.3毫摩尔),反应体系25℃下反应12h。旋干溶剂,残余物用乙酸乙酯溶液(5毫升)洗涤得到实施例11B化合物(120.0毫克,60.2%产率)。1H NMR(400MHz,CHLOROFORM-d)δ6.75(br.s.,1H),3.71(br.s.,1H),3.45-3.36(m,1H),2.26-2.17(m,1H),2.09-2.02(m,1H),1.59-1.10(m,25H),0.94-0.89(m,9H),0.66(s,3H).
实施例63
20℃氮气保护下,向化合物11B化合物(180.0毫克,414.1微摩尔)和羰基二咪唑(100.7毫克,621.2微摩尔)的二甲基甲酰胺(2.00毫升)、四氢呋喃(2毫升)溶液加入三乙胺(83.8毫克,828.2微摩尔,114.8微升),在70摄氏度搅拌12小时后,冷却到20摄氏度,加入水20毫升,加入乙酸乙酯(20毫升),用乙酸乙酯萃取(10毫升×3),将合并的有机层用饱和食盐水(10毫升)洗一次,有机相用无水硫酸钠干燥,过滤并蒸发,残余物通过过柱(二氯甲烷:甲醇=50:1)纯化得到实施例63化合物(72.0毫克,35.9%产率)。1HNMR(400MHz,CHLOROFORM-d)δppm 0.67(s,3H)0.79-1.11(m,11H)1.11-1.24(m,4H)1.28-1.99(m,26H)2.40-2.51(m,1H)2.55-2.66(m,1H)3.34-3.48(m,1H)3.72(br.s.,1H)。
路线12
实施例64
实施例12A
将实施例11A化合物(1.1克,2.5毫摩尔)溶在氨甲醇(14毫升)溶液中,60-70摄氏度搅拌18小时。旋干后的粗品通过柱层析得到实施例12A化合物(200.0毫克,产率19.0%)。1HNMR(400MHz,CHLOROFORM-d)δ=5.50(s,2H)3.72(br.s.,1H)3.36-3.50(m,1H)2.24-2.37(m,1H)2.09-2.19(m,1H)1.95-2.01(m,1H)1.56-1.95(m,9H)1.43-1.54(m,5H)1.30-1.42(m,5H)1.25-1.27(m,1H)1.13-1.24(m,3H)0.98-1.07(m,1H)0.89-0.98(m,9H)0.68(s,3H).
实施例12B
0摄氏度下,将Burgess试剂(85.0毫克,357.5微摩尔)加到化合物12A(150.0毫克,357.4微摩尔)的四氢呋喃(3毫升)溶液中。反应液在10-15摄氏度下搅拌3小时后用饱和食盐水(15毫升×2)洗涤,并用乙酸乙酯(10毫升×2)萃取。有机相用无水硫酸钠干燥后过滤,滤液真空旋干。粗品经薄层析制备板分离得到实施例12B化合物(30.0毫克,产率21.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.64-3.76(m,1H)3.34-3.50(m,1H)2.34-2.46(m,1H)2.22-2.34(m,1H)1.94-2.02(m,1H)1.85-1.91(m,2H)1.81(br.s.,4H)1.66-1.71(m,2H)1.56-1.63(m,2H)1.41-1.54(m,5H)1.31-1.41(m,4H)1.28-1.31(m,1H)1.14-1.24(m,3H)0.99-1.07(m,1H)0.97(d,J=6.53Hz,3H)0.84-0.95(m,6H)0.69(s,3H).
实施例64
将氧化二丁基锡(40.0毫克,74.7微摩尔)和三甲基硅基叠氮(52.0毫克,451.4微摩尔)加入到实施例12B化合物(30.0毫克,74.7微摩尔)的甲苯(2毫升)溶液中,并在100-110摄氏度搅拌18小时。反应完成后,反应液冷却至25-30摄氏度,用饱和食盐水(15毫升×2)洗涤,并用乙酸乙酯(8毫升×2)萃取。有机相用无水硫酸钠干燥后过滤,滤液真空旋干。粗品通过薄层析制备板分离得到实施例64化合物(7.0毫克,产率21.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.65-3.81(m,1H)3.33-3.39(m,1H)2.96-3.07(m,1H)2.83-2.95(m,1H)2.03-2.08(m,1H)1.72-2.02(m,6H)1.29-1.70(m,15H)1.12-1.21(m,2H)1.05-1.10(m,3H)0.97-1.04(m,1H)0.94(s,6H)0.70(s,3H).
路线13
实施例65
实施例13A
将3,4-二氢吡喃(1.6克,18.4毫摩尔),实施例12A化合物(1.0克,2.3毫摩尔)以及对甲苯磺酸(35.9毫克,0.2毫摩尔)的1,4-二氧六环(20毫升)混合物在25摄氏度下搅拌0.5小时。冷却并旋干后,残余物用乙酸乙酯萃取,依次用水、饱和食盐水洗涤,有机相旋干,通过硅胶色谱法纯化得到实施例13A化合物(1.3克,收率94%)。1H NMR(400MHz,CHLOROFORM-d)δ4.72(br.s.,1H),3.92(dd,J=6.3,10.8Hz,1H),3.79-3.58(m,4H),3.53-3.36(m,2H),2.40-2.30(m,1H),2.21(ddd,J=6.5,9.2,15.4Hz,1H),1.98-1.08(m,34H),1.06-0.75(m,13H),0.64(s,3H).
实施例13B
实施例13A化合物(500毫克,0.8毫摩尔)的四氢呋喃(5毫升)溶液在0摄氏度下加入四氢铝锂(94.4毫克,2.5毫摩尔),该混合物于0摄氏度下继续搅拌1小时后,加入94.4毫升水,过滤,滤液用乙酸乙酯稀释,碳酸氢钠水溶液洗涤,有机相旋干后得到实施例13B化合物(400毫克,收率84%),直接用于下步反应。1H NMR(400MHz,CHLOROFORM-d)δ4.74(d,J=3.01Hz,1H),3.84-3.97(m,1H),3.56-3.73(m,4H),3.37-3.54(m,3H),1.29-2.02(m,34H),1.06-1.20(m,5H),0.83-0.98(m,10H),0.66(s,3H).
实施例13C
向实施例13B化合物(230.0毫克,400.1微摩尔)的二氯甲烷(10毫升)溶液中一次性加入吡啶铬酸盐(215.0毫克,997.4微摩尔),混合液在18摄氏度下反应2小时。反应液过滤并旋干后,残余物通过制备板纯化得到实施例13C化合物(60.0毫克,26.0%产率)。1HNMR(400MHz,CHLOROFORM-d)δ9.76(br.s.,1H),4.66-4.77(m,1H),3.64-3.98(m,3H),3.32-3.58(m,3H),2.26-2.52(m,3H),1.06-2.00(m,37H),0.76-1.02(m,9H),0.64(s,3H).
实施例13D
向实施例13C化合物(150.0毫克,233.3微摩尔)的乙醇溶液(500毫升)中加入氰化钠(11.4毫克,233.3毫摩尔),氯化铵(12.5毫克,233.3毫摩尔),碳酸铵(22.4毫克,233.3毫摩尔)以及氨水(4.6毫升)。在60摄氏度下搅拌6小时,将反应液倒入冰水(50毫升)中,水层用乙酸乙酯(50毫升×3)萃取。将合并的有机层再用饱和食盐水(50毫升×2)洗,将有机层用硫酸钠干燥,过滤并蒸发,残余物通过制备板纯化得到实施例13D化合物(80.0毫克,收率72.1%)。1H NMR(400MHz,CHLOROFORM-d)δ8.50(br.s.,1H),6.15-6.36(m,1H),4.74(d,J=3.01Hz,1H),4.08(t,J=5.52Hz,1H),3.93(d,J=4.52Hz,1H),3.65-3.74(m,1H),3.39-3.55(m,6H),1.00-2.01(m,38H),0.82-0.98(m,9H),0.60-0.69(m,3H).
实施例65
0摄氏度下向乙酰氯(320.5毫克,4.1毫摩尔)的甲醇(2毫升)溶液中滴加实施例13D化合物(75.0毫克,116.7微摩尔)的甲醇(1毫升)溶液。0摄氏度下搅拌4小时,将反应液旋干,残余物通过制备板纯化得到实施例65化合物(55.0毫克,收率99.0%)。1H NMR(400MHz,METHANOL-d4)δ4.03-4.11(m,1H),3.65(br.s.,1H),3.35(s,1H),1.96-2.04(m,1H),1.67-1.95(m,7H),1.42-1.66(m,9H),1.24-1.41(m,5H),1.00-1.24(m,5H),0.94-1.00(m,3H),0.84-0.94(m,6H),0.70(s,3H).
路线14
实施例66A和66B
实施例14A
于实施例13C化合物(160.0毫克,0.3毫摩尔)的四氢呋喃(6毫升)溶液中加入三甲基三氟甲基硅醚(59.6毫克,0.4毫升)和四丁基氟化铵(10.9毫克,0.04毫摩尔),在0摄氏度下搅拌1小时,真空除去溶剂后,残余物通过硅胶柱层析法纯化得到实施例14A化合物,(60.0毫克,收率33.1%)。1H NMR(400MHz,CHLOROFORM-d)δ4.73(d,J=3.8Hz,1H),4.03-3.78(m,2H),3.70(br.s.,1H),3.58-3.35(m,2H),2.00-1.28(m,28H),1.22-1.01(m,5H),0.98-0.84(m,9H),0.71-0.60(m,3H).
实施例66A和66B
操作如同实施例65,以标题化合物14A为原料,纯化得到实施例66A化合物和实施例66B化合物(27.0毫克,收率61.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.92(dd,J=4.0,9.0Hz,1H),3.71(br.s.,1H),3.46-3.35(m,1H),2.86-2.65(m,1H),2.14(dt,J=3.8,12.8Hz,1H),1.98(d,J=11.8Hz,1H),1.81-1.63(m,6H),1.54-1.08(m,18H),1.05-0.87(m,10H),0.67(s,3H).和68B(10.0毫克,收率23.0%)。1H NMR(400MHz,CHLOROFORM-d)δ4.00-3.80(m,1H),3.70(br.s.,1H),3.48-3.34(m,1H),2.72(br.s.,1H),2.04-1.29(m,26H),1.23-1.07(m,4H),1.05-0.86(m,10H),0.67(d,J=4.5Hz,3H).
路线15
实施例67
实施例15A
向实施例2A化合物(100.0毫克,0.2毫摩尔)和醋酸铅(186.0毫克,0.4毫摩尔)的四氯化碳(2毫升)溶液中加入单质碘(106毫克,0.4毫摩尔),反应体系光照下反应12小时。加入硫代硫酸钠溶液(1毫升)淬灭反应,水层用二氯甲烷(10毫升×3)萃取,经硫酸钠干燥,过滤并旋干,残余物通过制备薄层板纯化(石油醚:乙酸乙酯=5:1)得到实施例15A化合物(50.0毫克,产率38.0%)。1H-NMR(CDCl3,400MHz)δ8.14(s,1H),8.03(s,1H),5.19(br.s.,1H),4.62-4.77(m,1H),3.23-3.32(m,1H),3.00-3.12(m,1H),1.96-2.02(m,2H),1.85-1.92(m,2H),1.70-1.82(m,7H),1.66-1.72(m,2H),1.39-1.45(m,2H),1.23-1.32(m,5H),1.09-1.19(m,6H),0.96(s,3H),0.90-0.93(m,6H),0.67(s,3H).
实施例15B
实施例15A化合物(100.0毫克,179微摩尔)的三乙基亚磷酸酯(149.0毫克,895微摩尔)混合物在160摄氏度下搅拌6小时。用水(5毫升)稀释后,用乙酸乙酯(10毫升×3)萃取,将合并的有机层用硫酸钠干燥,过滤并旋干,残余物通过制备薄层板纯化(石油醚:乙酸乙酯=1:1)得到实施例15B化合物(90.0毫克,收率84.1%)。1H-NMR(CDCl3,400MHz)δ8.12(s,1H),8.01(s,1H),5.16(br.s.,1H),4.62-4.73(m,1H),4.03-4.08(m,4H),1.82-1.97(m,3H),1.67-1.81(m,7H),1.55-1.65(m,2H),1.38-1.53(m,6H),1.29(t,J=7.0Hz,9H),1.19-1.26(m,3H),1.01-1.18(m,6H),0.86-0.91(m,6H),0.63(s,3H).
实施例67
参考实施例53,以化合物15B(40.0毫克,70.3微摩尔)为原料,得到实施例67化合物(30.0毫克,收率79.0%)。1H-NMR(CDCl3,400MHz)δ4.06-4.14(m,4H),3.71(br.s.,1H),3.42(d,J=8.0Hz,1H),1.88-2.01(m,2H),1.74-1.87(m,6H),1.62-1.73(m,3H),1.37-1.55(m,8H),1.33(s,6H),1.22-1.31(m,3H),1.12-1.21(m,4H),0.97-1.06(m,1H),0.94(d,J=6.8Hz,3H),0.87-0.92(m,6H),0.67(s,3H).
路线16
实施例68
实施例16A
零度下向N-叔丁氧羰基-1,2,5-噻二唑啉1,1-二氧化物(20.0毫克,89.5微摩尔)的N,N-二甲基甲酰胺(1毫升)溶液中加入钠氢(7.0毫克,179微摩尔)。半小时后,滴加实施例15A化合物(50.0毫克,89.5微摩尔)的N,N-二甲基甲酰胺(1毫升)溶液。滴加完毕后,反应体系缓慢升至室温后再反应1小时。用水(5毫升)淬灭反应,水层用乙酸乙酯(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并旋干,残余物通过制备薄层板纯化(石油醚:乙酸乙酯=1:1)得到化合物16A化合物(30.0毫克,收率57.5%)。1H-NMR(CDCl3,400MHz)δ8.15(s,1H),5.30(s,1H),5.18(br.s.,1H),3.90(t,J=6.5Hz,2H),3.78(s,2H),3.02-3.07(m,2H),1.97(d,J=12.0Hz,2H),1.79-1.88(m,5H),1.64(br.s.,5H),1.30(d,J=7.0Hz,6H),1.03-1.15(m,7H),0.94(s,3H),0.89(d,J=8.0Hz,6H),0.65(s,3H).
实施例68
参考实施例53,实施例16A化合物为原料(30.0毫克,57微摩尔)得到实施例68化合物(20.0毫克,67.1%产率)。1H-NMR(CDCl3,400MHz)δ4.22(br.s.,1H),3.71(br.s.,1H),3.52(q,J=6.5Hz,2H),3.39-3.47(m,2H),3.31-3.38(m,1H),2.97-3.10(m,2H),1.87-2.01(m,2H),1.80(d,J=8.8Hz,4H),1.67(br.s.,3H),1.40-1.52(m,5H),1.25-1.39(m,7H),1.12-1.24(m,4H),0.99(d,J=6.5Hz,3H),0.88-0.93(m,6H),0.68(s,3H).
实施例69和实施例70的制备参考实施例68的操作,通过路线16制备得到,所得结果如下:
路线17
实施例71
实施例17A
25摄氏度下,将碳酸银(197.5毫克,716.2微摩尔)加入至实施例15A化合物(200.0毫克,200.0微摩尔)的丙酮(2.8毫升)和水(150.0微升)的混合物溶液中。在25度下,搅拌30分钟,随后升温至80度,继续搅拌12小时。薄层色谱(石油醚:乙酸乙酯=2:1)检测发现有极性增大的新化合物生成。将反应悬浊液过滤,滤液减压除去溶剂得到剩余物。剩余物用薄层制备板(石油醚:乙酸乙酯=2:1)纯化得到实施例17A化合物(46.0毫克,27.2%收率,95%纯度)。1H NMR(400MHz,CHLOROFORM-d)δ8.15(s,1H),8.04(s,1H),5.20(br.s.,1H),4.80-4.62(m,1H),3.77-3.58(m,1H),2.07-1.95(m,1H),1.94-1.67(m,8H),1.53-1.40(m,5H),1.38-1.02(m,13H),0.99-0.87(m,9H),0.67(s,3H).
实施例17B
向实施例17A化合物(40.0毫克,89.2微摩尔)的甲苯(3毫升)溶液加乙基异氰酸酯(13.0毫克,178.4微摩尔),反应体系在110摄氏度下搅拌12小时。旋干溶剂,残余物通过制备薄层板纯化(石油醚:乙酸乙酯=2:1)得到实施例17B化合物(5毫克,9.7%产率)。1H-NMR(CDCl3,400MHz)δ8.15(s,1H),8.03-8.07(m,1H),5.19(br.s.,1H),4.64-4.77(m,1H),3.96(q,J=7.1Hz,2H),3.13-3.25(m,2H),1.89-2.02(m,2H),1.70-1.89(m,8H),1.56-1.66(m,4H),1.35-1.55(m,7H),1.27-1.33(m,4H),1.11-1.14(m,3H),0.94-0.97(m,6H),0.88-0.92(m,3H),0.66(s,3H).
实施例71
参考实施例53,以实施例17B化合物为原料,纯化得到实施例71化合物(5.0毫克,收率53.0%)。1H-NMR(CDCl3,400MHz)δ=4.60(br.s.,1H),4.00-4.15(m,2H),3.71(d,J=1.8Hz,1H),3.36-3.45(m,1H),3.16-3.27(m,2H),1.89-2.00(m,2H),1.74-1.85(m,5H),1.56-1.67(m,5H),1.40-1.51(m,6H),1.26-1.36(m,7H),1.14(s,3H),0.97(d,J=6.3Hz,3H),0.89-0.93(m,6H),0.67(s,3H).
路线18
实施例72
实施例18A
在0摄氏度下,将甲酸(8.2毫克,8.2微摩尔)滴入装有氯磺酸异氰酸酯(24.1毫克,24.1微摩尔)的圆底烧瓶中,在0度下搅拌5分钟,有白色固体产生。向反应体系中加入二氯甲烷(3.0毫升),并继续在0摄氏度下搅拌1小时,随后升温至25度,继续搅拌4小时。将反应液降至0度,将实施例17A化合物(50.0毫克,111.5微摩尔)和吡啶(13.5毫克,13.5微摩尔)的混合物加入至反应体系中。反应混合物升温至25度,继续搅拌12小时,减压蒸出溶剂,剩余物用薄层制备板(石油醚:乙酸乙酯=2:1)纯化,得到实施例18A化合物(18.0毫克,收率29.0%,纯度95%)。1H NMR(400MHz,CHLOROFORM-d)δ=8.15(s,1H),8.04(s,1H),5.20(br.s.,1H),4.79-4.65(m,3H),4.34-4.15(m,2H),2.07-1.69(m,11H),1.68-1.37(m,12H),1.35-1.04(m,13H),1.02-0.81(m,12H),0.73-0.61(m,4H).
实施例72
参考如同实施例53,以实施例18A化合物为原料,纯化得到实施例72化合物(10.0毫克,收率56.0%,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ=4.82(br.s.,2H),4.33-4.15(m,2H),3.71(br.s.,1H),3.49-3.33(m,1H),2.00-1.87(m,4H),1.84-1.73(m,5H),1.71-1.56(m,12H),1.53-1.38(m,11H),0.99(d,J=7.0Hz,5H),0.85(d,J=7.5Hz,10H),0.69-0.66(m,1H).
路线19
实施例73
实施例19A
将实施例15A化合物(1.5克,2.7毫摩尔)溶于N-甲基吡咯烷酮(8.0毫升),依次加入叠氮钠(1.5克,23.1毫摩尔)和醋酸(1.9克,32.3毫摩尔),反应液于20摄氏度搅拌20小时。加入饱和碳酸氢钠水溶液(5毫升)淬灭反应,用乙酸乙酯萃取(20毫升×3)。有机层经水洗涤(10毫升×4),无水硫酸钠干燥,过滤和浓缩,所得残留物经柱层析(硅胶)分离得到实施例19A化合物(1.2克,产率89.0%)。1H NMR(400MHz,CHLOROFORM-d)δ8.15(s,1H),8.04(s,1H),5.19(br.s.,1H),4.77-4.65(m,1H),3.35(ddd,J=4.8,8.2,12.4Hz,1H),3.20(td,J=7.9,12.2Hz,1H),1.99-1.70(m,10H),1.51-1.42(m,3H),1.18-1.08(m,5H),0.67(s,3H).
实施例19B
将实施例19A化合物(1.0克,2.1毫摩尔)溶于四氢呋喃(20.0毫升),在氮气保护下,依次加入三苯基膦(1.7克,6.3毫摩尔)和水(1.0毫升),反应液20度搅拌十二小时。浓缩除去溶剂,所得残留物经薄层层析色谱得到实施例19B化合物(500.0毫克,产率50.3%)。1HNMR(400MHz,CHLOROFORM-d)δ8.15(s,1H),8.04(s,1H),5.20(br.s.,1H),4.77-4.65(m,1H),3.02(br.s.,1H),2.89(br.s.,1H),2.01-1.70(m,14H),1.60-1.47(m,13H),1.21-1.13(m,18H),0.96(s,8H),0.79(d,J=2.5Hz,7H),0.68(s,3H).
实施例19C
将实施例19B化合物(50.0毫克,111.7微摩尔)溶于N,N-二甲基甲酰胺(1.0毫升)和二氯甲烷(2.0毫升),在0度下,依次加入碳酸氢钠(28.2毫克,335.1微摩尔)的水溶液(1.0毫升)和硫光气(15.4毫克,134.0微摩尔),反应液于20度反应三十分钟,加入水(10毫升),二氯甲烷萃取(10毫升×3)。有机层依次用水(10毫升)和饱和食盐水(10毫升)洗涤,经无水硫酸钠干燥,过滤浓缩,所得残留物溶于四氢呋喃(4.0毫升)中,在20摄氏度,依次加入(3R)-3-羟基吡咯盐酸盐(11.7毫克,94.5微摩尔)和三乙胺(13.6毫克,134.0微摩尔),反应液于80摄氏度搅拌4小时。浓缩除去溶剂,向残留物中加入水(5毫升),乙酸乙酯萃取(10毫升×3)。有机层经水洗涤(10毫升),无水硫酸钠干燥,过滤和浓缩,残留物经薄层层析色谱分离得到实施例19C化合物(40.0毫克,产率62.0%)。1H NMR(400MHz,METHANOL-d4)δ8.22(s,1H),8.08(s,1H),5.21(br.s.,1H),4.73-4.60(m,1H),4.44(br.s.,1H),3.77-3.57(m,3H),3.53-3.42(m,1H),2.11-1.85(m,7H),1.75(d,J=11.0Hz,3H),1.62-1.45(m,7H),1.26-1.10(m,10H),1.08-1.02(m,5H),0.88-0.81(m,6H),0.74(s,3H).
实施例73
参考实施例53,以实施例19C化合物为原料,纯化得到实施例73化合物(27.0毫克,产率71%)。1H NMR(400MHz,CHLOROFORM-d)δ5.27(t,J=4.5Hz,1H),4.52(br.s.,1H),3.69(br.s.,5H),3.60-3.48(m,1H),3.45-3.33(m,1H),2.13-2.05(m,2H),2.01-1.89(m,2H),1.86-1.57(m,9H),1.52-1.28(m,12H),1.20-1.15(m,2H),1.00(d,J=6.3Hz,4H),0.89-0.85(m,5H),0.60(br.s.,3H).
路线20
实施例74
实施例20A
将实施例19B化合物(80.0毫克,178.7微摩尔)溶于二氯甲烷(4.0毫升),然后依次加入二异丙基乙胺(34.6毫克,268.1微摩尔)和2-异丙基异氰酸酯(27.1毫克,268.1微摩尔),反应液于20度搅拌12小时。浓缩除去溶剂,所得残留物经薄层层析色谱分离得到实施例20A化合物(60.0毫克,产率58.0%)。1H NMR(400MHz,CHLOROFORM-d)δ8.15(s,1H),8.04(s,1H),5.19(br.s.,1H),4.78-4.63(m,1H),3.53-3.19(m,2H),1.98(d,J=12.3Hz,1H),1.92-1.84(m,2H),1.82-1.60(m,8H),1.53-1.40(m,6H),1.24(d,J=6.5Hz,7H),1.21-1.08(m,7H),0.98(d,J=6.5Hz,3H),0.95(s,3H),0.87(d,J=4.0Hz,4H),0.80-0.76(m,1H),0.65(s,3H).
实施例74
参考实施例53,以实施例20A化合物为原料,得到实施例74化合物(48.0毫克,产率85.0%)。1H NMR(400MHz,METHANOL-d4)δ3.67(br.s.,1H),3.56(br.s.,1H),3.36(br.s.,1H),2.03(d,J=12.0Hz,1H),2.00-1.82(m,4H),1.81-1.72(m,3H),1.65-1.48(m,7H),1.44-1.28(m,8H),1.19(d,J=6.5Hz,6H),1.03(d,J=6.3Hz,3H),0.93-0.86(m,5H),0.73(s,3H).
路线21
实施例75
实施例21A
将实施例12A化合物(5.0克,11.5毫摩尔)溶于无水甲苯(80.0毫升)中,然后加入碳酸银/硅藻土(12.6克,46.0毫摩尔),反应液于130摄氏度下搅拌十二小时。冷至室温后,浓缩除去溶剂。残留物经柱层析(硅胶)得到实施例21A化合物(3.6克,产率69.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.78(br.s.,1H),3.67(s,3H),3.07(t,J=14.6Hz,1H),2.47-2.31(m,2H),2.28-2.09(m,3H),2.06-1.87(m,4H),1.75-1.17(m,21H),1.00(s,3H),0.95-0.83(m,10H),0.70(s,3H).
实施例21B
在氮气保护下,向钠氢(40.0毫克,1.7毫摩尔)的无水甲苯悬浊液(20毫升)中滴加实施例21A化合物(601.4毫克,1.4毫摩尔)的甲苯溶液(3毫升),然后再逐滴加入甲酸乙酯(308.9毫克,4.2毫摩尔)的甲苯溶液(2毫升),20摄氏度搅拌1小时。然后加入无水乙醇(76.8毫克,1.7毫摩尔),继续搅拌11小时。将反应液倒入冰水中,乙酸乙酯萃取(20毫升×3),合并的有机相经饱和食盐水(10毫升×2)洗涤,无水硫酸钠干燥,过滤和浓缩得到实施例21B化合物(500.0毫克,72.0%产率)。1H NMR(400MHz,CHLOROFORM-d)δ14.29(br.s.,1H),8.20(s,1H),4.14(q,J=7.0Hz,3H),3.79(br.s.,1H),3.68(s,1H),3.41-3.29(m,1H),2.27-2.16(m,2H),1.88-1.76(m,2H),1.56-1.30(m,15H),1.20-1.11(m,4H),1.05(s,3H),0.99-0.90(m,9H),0.69(s,3H).
实施例21C
将实施例21B化合物(100.0毫克,210.7微摩尔)溶于乙醇(3.00毫升),向所得溶液中加入水合肼(21.1毫克,421.4微摩尔),反应液在80摄氏度下搅拌1小时。浓缩除去溶剂,所得残留物经薄层层析色谱分离得到标题化合物21C(65.0毫克,产率62.0%,白色固体)。1H NMR(400MHz,CHLOROFORM-d)δ7.32(br.s.,1H),4.11(q,J=7.1Hz,3H),3.81(br.s.,1H),3.55-3.44(m,1H),2.78(d,J=15.8Hz,1H),2.62(dd,J=6.9,17.7Hz,1H),2.43-2.26(m,1H),2.23-2.09(m,3H),1.96-1.73(m,7H),1.67-1.52(m,4H),1.46-1.35(m,3H),1.30-1.20(m,7H),1.10-1.03(m,5H),0.89(d,J=6.3Hz,4H),0.66(s,3H).
实施例75
将实施例21C化合物(65.0毫克,138.1微摩尔)溶于四氢呋喃(4.0毫升)中,然后加入氢氧化钠(55.2毫克,1.4毫摩尔)的水溶液(2.0毫升),反应液于30摄氏度搅拌12小时。用1N的稀盐酸酸化至pH为2-3,乙酸乙酯萃取(10毫升×3),有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩,所得残留物经薄层层析色谱分离得到实施例75化合物(14.0毫克,产率22.0%)。1H NMR(400MHz,METHANOL-d4)δ7.22(s,1H),3.77(br.s.,1H),3.62(dd,J=10.8,17.6Hz,1H),2.82(d,J=15.8Hz,1H),2.58(dd,J=7.4,17.7Hz,1H),2.40-2.26(m,1H),2.23-2.08(m,2H),1.99-1.73(m,6H),1.69-1.47(m,4H),1.46-1.24(m,8H),1.12(s,4H),1.00(t,J=7.3Hz,3H),0.94(d,J=6.5Hz,3H),0.72(s,3H).
路线22
实施例76
实施例22A
将实施例21C化合物(90.0毫克,191.2微摩尔)溶于N,N-二甲基甲酰胺(4.0毫升),然后加入硫酸二甲酯(440.0毫克,3.5毫摩尔)和碳酸钾(79.3毫克,573.6微摩尔),反应液于30摄氏度搅拌12小时。浓缩除去溶剂,所得残留经薄层层析色谱分离得到实施例22A的混合物(20.0毫克,19.0%产率,白色固体)。1H NMR(400MHz,METHANOL-d4)δ7.15(s,1H),4.18-4.06(m,2H),3.78(s,3H),3.56(dt,J=10.7,17.0Hz,1H),2.78(dd,J=6.7,15.9Hz,1H),2.52(td,J=6.3,17.7Hz,1H),2.41-2.27(m,1H),2.18(s,1H),1.98-1.52(m,11H),1.43-1.32(m,5H),1.25(t,J=7.0Hz,4H),0.71(s,3H).
实施例76
参考实施例53的操作方法,以实施例22A化合物(20.0毫克,37.1微摩尔)为原料,用LiOH脱除乙氧基,后经薄层层析色谱分离得到实施例76化合物(10.0毫克,产率50%)。1HNMR(400MHz,CHLOROFORM-d)δ7.17(s,1H),6.96(s,1H),3.81(s,3H),3.70(s,1H),2.74(d,J=15.8Hz,1H),2.67-2.58(m,1H),2.58-2.20(m,3H),2.13(d,J=15.8Hz,1H),1.94-1.69(m,5H),1.65-1.48(m,4H),1.48-1.22(m,10H),1.15-0.79(m,15H),0.67(s,3H).
路线23
实施例77
实施例23A
将实施例21B化合物(400.0毫克,895.6微摩尔)溶于甲醇(10.0毫升)后,再加入硼氢化钠(203.3毫克,5.4毫摩尔),反应液于0摄氏度下搅拌1小时。加入饱和氯化铵溶液(5毫升)淬灭反应,浓缩除去溶剂,向残留物中加入水(5毫升),用乙酸乙酯萃取(10毫升×3)。有机层经水洗涤(10毫升),无水硫酸钠干燥,过滤和浓缩,所得残留物经薄层层析色谱得到实施例23A化合物(120.0毫克,产率28.0%,无色油状物)。1H NMR(400MHz,CHLOROFORM-d)δ4.10(q,J=7.1Hz,2H),3.68(br.s.,1H),3.64(s,1H),3.38(tt,J=5.1,10.0Hz,1H),2.39-2.27(m,1H),2.23-2.13(m,1H),1.98-1.84(m,3H),1.65-1.54(m,3H),1.45-1.36(m,5H),1.31-1.24(m,6H),1.17-1.10(m,3H),0.90(s,3H),0.67-0.61(m,3H).
实施例77
以实施例23A化合物为原料(100.0毫克,208.9微摩尔),参考实施例65的制备方法,经薄层层析色谱分离得到实施例77化合物(20.0毫克,产率20.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.71(br.s.,1H),3.62(t,J=5.6Hz,2H),3.47-3.36(m,1H),1.98(d,J=12.0Hz,1H),1.92-1.75(m,5H),1.69-1.56(m,8H),1.51-1.39(m,9H),1.19-1.06(m,7H),0.95-0.92(m,4H),0.89-0.85(m,8H),0.82-0.76(m,2H),0.67(s,3H).
路线24
实施例78
实施例24A
实施例21A化合物(10.0克,23.1毫摩尔)溶于吡啶(100毫升)中,加入醋酐(28.3克,277.4毫摩尔)和4-N,N-二甲基氨基吡啶(282.4毫克,2.3毫摩尔),110摄氏度回流6小时,TLC检测反应结束,浓缩除去溶剂,所得残留物经薄层层析色谱分离得到实施例24A化合物(9.2克,产率84.0%)。1H NMR(400MHz,CHLOROFORM-d)δ5.19(br.s.,1H),3.68(s,3H),2.81(t,J=14.3Hz,1H),2.49-2.39(m,1H),2.35-1.99(m,9H),1.94-1.73(m,5H),1.71-1.08(m,15H),1.09-1.00(m,3H),0.99-0.84(m,6H),0.75-0.63(m,3H).
实施例24B
将二乙胺基三氟化硫(132.4毫克,821.6微摩尔)滴加到实施例24A化合物(130.0毫克,273.9微摩尔)的二氯甲烷(3.0毫升)溶液中,并在25-30摄氏度搅拌18小时。反应完成后,反应液用冰水淬灭,乙酸乙酯(10毫升×2)萃取、有机相用饱和食盐水(15毫升×2)洗涤,无水硫酸钠干燥、过滤,减压浓缩得到粗品。粗品经薄层层析制备板(石油醚/乙酸乙酯=10/1)分离纯化得到实施例24B化合物(75.0毫克,产率50.1%,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ0.67(s,3H)0.88-0.97(m,6H)0.97-1.04(m,3H)1.05-1.23(m,5H)1.32-1.41(m,3H)1.43-1.54(m,3H)1.57-1.69(m,6H)1.78-1.90(m,6H)1.96-2.04(m,1H)2.07-2.12(m,3H)2.12-2.31(m,2H)2.32-2.43(m,1H)3.68(s,3H)5.09-5.19(m,1H).
实施例78
操作同标题化合物53,以化合物24B为原料(75.0毫克,151.0微摩尔),反应处理并纯化得到标题化合物78(55.0毫克,产率74.0%,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ0.69(s,3H)0.90-0.99(m,9H)1.13-1.25(m,3H)1.31-1.54(m,10H)1.55-1.79(m,5H)1.80-1.87(m,3H)1.87-1.97(m,2H)1.97-2.03(m,1H)2.20-2.53(m,3H)3.75(br.s.,1H).
路线25
实施例79A和79B
实施例25A
将一水合氢氧化锂(35.3毫克,1.5毫摩)加入到实施例24A化合物(100.0毫克,0.2毫摩尔)的甲醇(2毫升)和水(0.5毫升)的混合溶液中,20-25摄氏度搅拌18小时。待反应完成后,反应液用2M稀盐酸酸化后,用饱和食盐水(15毫升×2)洗涤,并用乙酸乙酯(10毫升×2)萃取,无水硫酸钠干燥过滤,滤液减压旋干。粗品经薄层层析制备板分离(二氯甲烷/甲醇=20/1)得到实施例25A化合物(60.0毫克,产率88.0%)。1H NMR(400MHz,CHLOROFORM-d)δ=5.17(br.s.,1H)2.70-2.89(m,1H)2.34-2.49(m,2H)2.23(d,J=3.51Hz,3H)2.06(s,3H)1.98-2.05(m,2H)1.74-1.90(m,5H)1.60-1.70(m,1H)1.29-1.58(m,8H)1.08-1.24(m,5H)1.01-1.06(m,3H)0.86-0.97(m,6H)0.63-0.72(m,3H).
实施例25B
0摄氏度氮气保护下,将甲基溴化镁(0.4毫升,651.2微摩,3N)的乙醚溶液滴加到实施例25A化合物(60.0毫克,130.2微摩)的四氢呋喃(4毫升)溶液中并搅拌2小时。反应完成后,用饱和氯化铵溶液淬灭,乙酸乙酯(10毫升×2)萃取。有机相用饱和食盐水(15毫升×2)洗涤,无水硫酸钠干燥过滤并减压浓缩。粗品经薄层层析制备板分离(二氯甲烷/甲醇=20/1)得到实施例25B化合物。
实施例25B1化合物(35.0毫克,产率56.0%)。1H NMR(400MHz,CHLOROFORM-d)δ5.03-5.14(m,1H)2.31-2.43(m,1H)2.18-2.30(m,1H)2.04(s,3H)1.90-2.00(m,1H)1.72-1.86(m,4H)1.53-1.69(m,4H)1.26-1.51(m,11H)1.19-1.23(m,3H)1.01-1.17(m,5H)0.94-0.99(m,3H)0.85-0.94(m,6H)0.64(s,3H).
实施例25B2化合物(15.0毫克,产率24.0%)。1H NMR(400MHz,CHLOROFORM-d)δ5.04-5.13(m,1H)2.33-2.42(m,1H)2.19-2.30(m,1H)2.05-2.09(m,3H)1.86-2.03(m,3H)1.73-1.84(m,5H)1.29-1.61(m,12H)1.21(s,3H)1.06-1.15(m,5H)0.90-0.95(m,6H)0.84-0.90(m,3H)0.59-0.67(m,3H).
实施例79A和79B
将氢氧化钠(1.5克,37.5毫摩)加入到实施例25B1化合物(35.0毫克,73.4微摩)的甲醇(2.0毫升)溶液中,70-80摄氏度搅拌55小时。反应完成后,用2N的稀盐酸酸化至pH值约等于5,乙酸乙酯(8毫升×2)萃取,有机相用饱和食盐水(10毫升×2)洗涤,无水硫酸钠干燥,过滤,减压蒸干。粗品经薄层层析板(二氯甲烷/甲醇=15/1)纯化得到实施例79A化合物(20.0毫克,产率63.0%)。1H NMR(400MHz,CHLOROFORM-d)δ3.66-3.77(m,1H)2.33-2.44(m,1H)2.19-2.30(m,1H)1.76-1.99(m,4H)1.53-1.73(m,5H)1.29-1.51(m,12H)1.25-1.27(m,1H)1.10-1.23(m,6H)0.79-1.01(m,9H)0.66(s,3H).
操作同实施例79A化合物,以实施例25B2化合物(15.0毫克,31.5微摩)为原料,粗品经薄层层析(二氯甲烷/甲醇=15/1)纯化得到实施例79B化合物(6.0毫克,产率44.0%)。1HNMR(400MHz,CHLOROFORM-d)δ3.62-3.72(m,1H),2.33-2.46(m,1H),2.19-2.30(m,1H),1.87-2.08(m,3H),1.72-1.86(m,3H),1.52-1.69(m,3H),1.27-1.52(m,13H),1.19(s,3H),1.02-1.15(m,3H),0.87-0.95(m,9H),0.65(s,3H).
路线26
实施例80
实施例26A
0摄氏度氮气保护下,将Tebbe试剂(0.5M甲苯溶液,0.1毫摩)加入到实施例24A化合物(60.0毫克,0.1微摩)的四氢呋喃(2.0毫升)溶液中。0摄氏度搅拌4小时后,升至25-30摄氏度搅拌16小时。将2毫升2M的氢氧化钠水溶液加到反应液中并过滤,滤液用乙酸乙酯(10毫升×2)萃取,有机相用饱和食盐水(15毫升×2)洗涤,无水硫酸钠干燥,过滤,减压旋干。粗品经薄层层析(石油醚/乙酸乙酯=5/1)纯化,得到实施例26A化合物(33.0毫克,产率55.0%)。1H NMR(400MHz,CHLOROFORM-d)δ5.02-5.19(m,1H)4.56(br.s.,2H)3.67(s,3H)2.42-2.56(m,1H)2.31-2.42(m,1H)2.20-2.29(m,1H)2.10-2.20(m,1H)2.07(s,3H)1.72-2.04(m,8H)1.58-1.71(m,2H)1.47-1.57(m,2H)1.30-1.47(m,5H)1.02-1.24(m,6H)0.83-0.99(m,9H)0.67(s,3H).
实施例26B
氮气保护下,将二乙基锌(22.9毫克,185.8微摩)和二碘甲烷(79.6毫克,297.2微摩)依次加入到实施例26A化合物(40.0毫克,92.9微摩)的甲苯(2.0毫升)溶液中。25-30摄氏度搅拌0.5小时,此过程中反应液逐步变为白色悬浊液。之后用氧气置换氮气,此过程中悬浊液由白色变为粉色。之后反应液在65-75摄氏度搅拌3.5小时,此过程中悬浊液由粉色变为浅黄色。反应完成后,反应液冷却至室温,用饱和氯化氨溶液(10毫升)淬灭,乙酸乙酯(10毫升×3)萃取,有机相用饱和食盐水(15毫升×2)洗涤,无水硫酸钠干燥,过滤,减压旋干。粗品经薄层层析(石油醚/乙酸乙酯=10/1)纯化,得到实施例26B化合物(30.0毫克,产率69%)。1H NMR(400MHz,CHLOROFORM-d)δ0.03-0.17(m,2H)0.20-0.30(m,2H)0.44-0.64(m,2H)0.68(s,3H)0.88(t,J=7.40Hz,3H)0.92-0.97(m,6H)1.15-1.24(m,4H)1.28-1.55(m,11H)1.62-1.69(m,2H)1.71-1.87(m,4H)1.89-2.00(m,2H)2.22-2.29(m,1H)2.32-2.39(m,1H)3.68(s,3H)3.69-3.73(m,1H).
实施例80
操作同实施例53,原料为化合物26B(30.0毫克,67.5微摩),经薄层层析(石油醚/乙酸乙酯=3/1)纯化得到标题化合物80(20.0毫克,产率65%)。1H NMR(400MHz,CHLOROFORM-d)δ0.03-0.16(m,2H)0.18-0.28(m,2H)0.43-0.62(m,2H)0.67(s,3H)0.84-0.89(m,3H)0.92-0.96(m,6H)1.12-1.23(m,4H)1.26-1.28(m,1H)1.28-1.38(m,4H)1.38-1.45(m,3H)1.45-1.54(m,3H)1.60-1.68(m,2H)1.72-1.77(m,1H)1.79-1.85(m,2H)1.87-1.93(m,1H)1.93-1.99(m,1H)2.20-2.33(m,2H)2.36-2.45(m,1H)3.65-3.73(m,1H).
路线27
实施例81
实施例27A
氮气保护下,将干钯/碳(5.0毫克)加入到化合物26A(33.0毫克,69.8微摩)的甲醇(4毫升)溶液中,并用氢气球置换三次后,将反应液在1个大气压的氢气下20-28摄氏度搅拌18小时。之后反应液过滤,减压旋干溶剂得到实施例27A化合物(25.0毫克,产率75%)。1HNMR(400MHz,CHLOROFORM-d)δ5.01-5.16(m,1H)3.68(s,3H)2.30-2.44(m,1H)2.17-2.29(m,1H)2.07(s,3H)1.92-2.05(m,2H)1.68-1.89(m,5H)1.41-1.62(m,5H)1.30-1.41(m,5H)1.09-1.23(m,6H)0.97-1.05(m,2H)0.83-0.95(m,13H)0.66(s,3H).
实施例81
操作同实施例53,以化合物27A(50.0毫克,105.3微摩尔)为原料,粗品经薄层层析(石油醚/乙酸乙酯=1/1)纯化得到标题化合物81(30.0毫克,产率68%)。1H NMR(400MHz,CHLOROFORM-d)δ3.66-3.78(m,1H)2.36-2.47(m,1H)2.22-2.33(m,1H)1.91-2.00(m,2H)1.78-1.88(m,2H)1.61-1.71(m,2H)1.43-1.55(m,6H)1.21-1.43(m,9H)1.20(br.s.,3H)0.98-1.07(m,2H)0.88-0.97(m,12H)0.68(s,3H).
路线28
实施例82A和82B
实施例28A
将硼烷四氢呋喃溶液(1M,58.0微摩)加入到实施例26A化合物(25.0毫克,58.0微摩)的四氢呋喃(1.5毫升)溶液中,25-30摄氏度搅拌4小时。反应完成后,将反应液冷却至0摄氏度,并依次加入水(0.1毫升),5摩尔的氢氧化钠水溶液(0.2毫升)和双氧水(30%水溶液,6.9毫摩)。25-30摄氏度搅拌3小时。反应完成后,反应液用饱和亚硫酸钠溶液(2毫升)淬灭,乙酸乙酯(8毫升×2)萃取,有机相用饱和食盐水(10毫升×2)洗涤,用无水硫酸钠干燥,过滤,减压旋干。粗品经薄层层析(石油醚/乙酸乙酯=3/1)纯化得到实施例28A1化合物(6.0毫克,产率14%,纯度60%)。1H NMR(400MHz,CHLOROFORM-d)δ3.70-3.75(m,1H),3.68(s,3H),3.57-3.67(m,2H),2.32-2.42(m,1H),2.19-2.29(m,1H),1.76-2.03(m,6H),1.54-1.69(m,6H),1.33-1.50(m,10H),1.13-1.23(m,4H),0.88-0.97(m,9H),0.68(s,3H).和实施例28A1化合物(9.0毫克,产率28%,纯度80%)。1H NMR(400MHz,CHLOROFORM-d)δ3.69-3.74(m,1H),3.66(s,3H),3.41-3.51(m,2H),2.29-2.40(m,1H),2.16-2.27(m,1H),1.84-1.97(m,3H),1.67-1.82(m,3H),1.56-1.66(m,6H),1.39-1.51(m,8H),1.30(d,J=3.01Hz,2H),1.06-1.22(m,4H),0.91(s,9H),0.66(s,3H).
实施例82A和82B
操作同实施例53,化合物28A1(35.0毫克,78.0微摩)和28A2(25.0毫克,55.7微摩)为原料,粗品经薄层层析(石油醚/乙酸乙酯/醋酸=20毫升/20毫升/1滴)纯化得到实施例82A化合物和实施例82B化合物。
实施例82A化合物(15.0毫克,产率44%)1H NMR(400MHz,CHLOROFORM-d)δ3.68-3.74(m,1H),3.54-3.68(m,2H),2.30-2.44(m,1H),2.17-2.30(m,1H),1.74-2.03(m,6H),1.28-1.70(m,15H),1.06-1.24(m,5H),0.81-0.98(m,9H),0.65(s,3H).
实施例82B化合物(10.0毫克,产率39%,纯度95%)。1H NMR(400MHz,CHLOROFORM-d)δ3.66-3.77(m,1H),3.41-3.48(m,2H),2.33-2.44(m,1H),2.19-2.30(m,1H),1.80-1.94(m,3H),1.58-1.71(m,3H),1.42-1.54(m,7H),1.29-1.41(m,5H),1.23-1.25(m,3H),1.12-1.21(m,3H),0.98-1.09(m,2H),0.87-0.94(m,9H),0.65(s,3H).
路线29
实施例83
0摄氏度下,将钠氢(13.2毫克,552.2微摩尔)加入到化合物11A(40.0毫克,92.0微摩尔)的N,N-二甲基甲酰胺(1毫升)和四氢呋喃(2毫升)混合溶液中搅拌5分钟后,将碘甲烷(270.0毫克,1.9毫摩尔)加入到反应液中,25-30摄氏度搅拌18小时。薄层制备层析板监测显示反应完成后,反应液用乙酸乙酯(10毫升×2)萃取、有机相用饱和食盐水(15毫升×2)洗涤、无水硫酸钠干燥、过滤。滤液减压浓缩的粗品经薄层层析柱纯化(石油醚/乙酸乙酯=7/3)得到实施例83化合物(20毫克,产率48%,纯度95%)。1H NMR(400MHz,CHLOROFORM-d)δ0.68(s,3H)0.89-1.00(m,10H)1.11-1.21(m,3H)1.31-1.70(m,12H)1.71-2.02(m,9H)2.22-2.32(m,1H)2.37-2.48(m,1H)2.93-3.06(m,1H)3.36(s,3H)3.68-3.75(m,1H).
路线30
实施例84
实施例30A
零下60摄氏度并在氮气保护下,将正丁基锂(0.1毫升,2.5摩每升的正己烷溶液)加入到甲氧甲基三苯基氯化磷(151.7毫克,442.4微摩尔)的乙醚(5.0毫升)溶液中后,反应液在25-30摄氏度搅拌半小时,期间血红色的膦叶立德生成。然后在冰浴下,将实施例24A化合物(70.0毫克,147.5微摩尔)的四氢呋喃(2.0毫升)溶液滴加到反应液中,25-30摄氏度搅拌3小时。反应液用饱和氯化氨溶液淬灭,之后用乙酸乙酯(10毫升×2)萃取。有机相用饱和食盐水(15毫升×2)洗涤,无水硫酸钠干燥、过滤,减压浓缩得到粗品。粗品经薄层层析制备板分离纯化得到实施例30A化合物(30.0毫克,产率38%,纯度95%)。1H NMR(400MHz,CHLOROFORM-d)δ0.55-0.72(m,3H)0.82-0.94(m,10H)1.03-1.20(m,5H)1.23-1.34(m,7H)1.44-1.54(m,2H)1.57-1.63(m,1H)1.69-1.88(m,7H)1.90-1.99(m,2H)2.05(d,J=3.51Hz,3H)2.17-2.27(m,1H)2.31-2.38(m,1H)2.42-2.59(m,1H)3.44-3.58(m,3H)3.58-3.75(m,3H)4.96-5.15(m,1H)5.74(s,1H).
实施例30B
将浓盐酸(12M,200.0微升)滴加到实施例30A化合物(30.0毫克,59.7微摩尔)的二氧六环(2.0毫升)溶液中,25-30摄氏度搅拌2小时。反应完成后,反应液用乙酸乙酯(10毫升×2)萃取,有机相用饱和食盐水(15毫升×2)洗涤,无水硫酸钠干燥、过滤,减压浓缩得到粗品。粗品经薄层层析制备板(石油醚/乙酸乙酯=8/1)分离纯化得到实施例30B化合物(15.0毫克,42%产率,纯度85%)。1H NMR(400MHz,CHLOROFORM-d)δ0.64(s,3H)0.82-0.94(m,7H)0.94-1.03(m,3H)1.04-1.17(m,5H)1.31-1.39(m,3H)1.40-1.52(m,3H)1.55-1.62(m,1H)1.68(br.s.,6H)1.74-1.89(m,4H)1.92-1.99(m,2H)2.04(s,6H)2.15-2.25(m,1H)2.28-2.38(m,1H)3.66(d,J=2.01Hz,1H)3.70(s,1H)5.04-5.13(m,1H)9.62-9.65(m,1H).
实施例30C
将二乙胺基三氟化硫(82.5毫克,511.6微摩尔)滴加到实施例30B化合物(50.0毫克,102.3微摩尔)的二氯甲烷(2.0毫升)溶液中,并在25-30摄氏度搅拌36小时。反应完成后,反应液用冰水淬灭,乙酸乙酯(10毫升×3)萃取,有机相用饱和食盐水(15毫升×3)洗涤,无水硫酸钠干燥、过滤,减压浓缩得到粗品。粗品经薄层层析制备板(石油醚/乙酸乙酯=8/1)分离纯化得到实施例30C化合物(40.0毫克,产率69%,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ0.66(s,3H)0.87-1.00(m,9H)1.02-1.21(m,6H)1.28(br.s.,6H)1.42-1.55(m,4H)1.55-1.72(m,5H)1.75-1.87(m,3H)1.91-2.02(m,2H)2.04-2.09(m,3H)2.17-2.29(m,1H)2.31-2.42(m,1H)3.68(s,3H)5.06-5.17(m,1H)5.40-5.75(m,1H).
实施例84
以化合物30C(40.0毫克,78.33微摩尔)为原料,操作同实施例53,反应后处理所得粗品经薄层层析制备板(石油醚/乙酸乙酯=3/1)分离纯化得到实施例84化合物(25.0毫克,产率67%,纯度95%),为白色固体。1H NMR(400MHz,CHLOROFORM-d)δ0.66(s,3H)0.85-0.95(m,9H)0.95-1.04(m,1H)1.07-1.22(m,4H)1.24-1.25(m,1H)1.27-1.54(m,10H)1.54-2.00(m,10H)2.18-2.31(m,1H)2.33-2.45(m,1H)3.71(br.s.,1H)5.32-6.09(m,1H).
路线31
实施例85
实施例31A
将化合物19B(20.0毫克,44.7毫摩尔)溶于二氯甲烷(3.0毫升),依次加入N,N-二甲基-4-氨基吡啶(1.1毫克,9.0毫摩尔)和苯基磺酰氯(11.8毫克,67.0毫摩尔)的二氯甲烷溶液(1毫升),20摄氏度搅拌12小时。浓缩除去溶剂,所得残留物经薄层层析色谱分离得到实施例31A化合物(12.0毫克,产率48%,近无色液体)。1H NMR(400MHz,CHLOROFORM-d)δ8.13(s,1H),7.87(d,J=7.5Hz,2H),7.62-7.48(m,3H),5.17(br.s.,1H),3.52-3.47(m,2H),3.08-2.99(m,1H),2.97-2.88(m,1H),1.94-1.67(m,8H),1.51-1.24(m,10H),1.20-0.99(m,9H),0.93-0.81(m,9H),0.60(s,3H).
实施例85
参考同实施例53的操作步骤,以化合物31A为原料(42.0毫克,75.0毫摩尔),纯化得到实施例85化合物(15.0毫克,产率37.59%)。1H NMR(400MHz,CHLOROFORM-d)δ7.87(d,J=7.3Hz,2H),7.62-7.56(m,1H),7.56-7.50(m,2H),4.31(t,J=5.9Hz,1H),3.48-3.32(m,1H),3.10-2.86(m,2H),1.92(d,J=12.0Hz,1H),1.86-1.71(m,5H),1.69-1.52(m,7H),1.50-1.25(m,11H),1.20-1.06(m,5H),0.89(s,4H),0.85(d,J=6.5Hz,3H),0.66-0.55(m,3H).
实施例86和实施例87的制备参考实施例85的操作,通过路线31制备得到,所得结果如下:
路线32
实施例88
20摄氏度下,将碳酸钾(27.8毫克,27.8微摩尔)和硫酸二甲酯(25.3毫克,25.3微摩尔)加入实施例2化合物(40.0毫克,80.4微摩尔)的丙酮(1.0毫升)溶液中。混合搅拌12小时。薄层色谱(石油醚/乙酸乙酯=1/2)检测反应完全。减压旋蒸出溶剂,并用薄层制备板(石油醚/乙酸乙酯=1/2)分离纯化得实施例88化合物(23.0毫克,收率13%,白色固体)。1HNMR(400MHz,METHANOL-d4)δ3.68(br.s.,1H),3.29(s,6H),2.81-2.53(m,2H),2.02-1.29(m,20H),1.23-0.98(m,7H),0.96-0.87(m,6H),0.73(s,3H).
路线33
实施例89
实施例33A
向实施例11A化合物(5.0克,11.5毫摩尔)的吡啶溶液(20毫升)中加醋酸酐(7.1克,69.1毫摩尔)和N,N二甲氨基吡啶(140.5毫克,1.2毫摩尔),反应液在80摄氏度下搅拌12小时。旋干溶剂,体系用饱和碳酸氢钠水溶液(10毫升)洗,反应体系用乙酸乙酯(15毫升×3)萃取,将合并的有机层用硫酸钠干燥,过滤并蒸发得到实施例33A化合物(5.0克,84%产率)。1H-NMR(CDCl3,400MHz)δ5.10(br.s.,1H),4.43(d,J=5.0Hz,1H),3.67(s,3H),2.40-2.18(m,2H),2.08(s,3H),2.05(s,3H),1.90-1.67(m,9H),1.52-1.29(m,10H),1.17-0.99(m,6H),0.94-0.91(m,6H),0.91-0.87(m,3H),0.65(s,3H)。
实施例33B
向实施例33A化合物(100.0毫克,193.0微摩尔)的甲醇溶液中加盐酸(12M,0.2毫升)混合物在20摄氏度下搅拌12小时。旋干溶剂,体系用饱和碳酸氢钠水溶液(10毫升)洗,反应体系用乙酸乙酯(15毫升×3)萃取,将合并的有机层用硫酸钠干燥,过滤并蒸发得到实施例33B化合物(90.0毫克,98%产率)。1H-NMR(CDCl3,400MHz)δ5.10(br.s.,1H),3.67(s,3H),3.47(d,J=5.0Hz,1H),2.40-2.18(m,2H),2.08(s,3H),1.90-1.67(m,9H),1.52-1.29(m,10H),1.17-0.99(m,6H),0.94-0.91(m,6H),0.91-0.87(m,3H),0.65(s,3H)。
实施例33C
向实施例33B化合物(100.0毫克,209.0微摩尔),三苯基磷(304.0毫克,1.2毫摩尔)和咪唑(83.0毫克,1.2微摩尔)的甲苯(8毫升)和乙腈溶液(2毫升)加碘(266.0毫克,1.1毫摩尔)。20摄氏度下反应1小时,饱和亚硫酸钠溶液(10毫升)加入反应体系,水层用乙酸乙酯(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发,残余物通过制备薄层板纯化(石油醚/乙酸乙酯=10/1)得到实施例33C化合物(100.0毫克,81%)。1H-NMR(CDCl3,400MHz)δ5.07(br.s.,1H),5.01(br.s.,1H),3.71-3.60(m,3H),2.39-2.29(m,1H),2.27-2.15(m,1H),2.04(s,3H),2.00-1.93(m,1H),1.88-1.74(m,6H),1.73-1.58(m,5H),1.55-1.38(m,4H),1.36-1.20(m,5H),1.17-1.06(m,4H),1.03(s,3H),0.93-0.87(m,6H),0.68-0.61(m,3H)。
实施例33D
向实施例33C化合物(2.3克,3.9毫摩尔),吡唑(534.0毫克,7.8毫摩尔)的DMF(30毫升)加碳酸钾(1.0克,7.8毫摩尔)。60摄氏度下反应12小时,水(50毫升)加入反应体系,水层用乙酸乙酯(30毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发,残余物通过柱色谱纯化(石油醚/乙酸乙酯=20/1)得到实施例33D化合物(1.4克,78%)。1H NMR(CDCl3,400MHz)δ5.70-5.44(m,2H),5.13(br.s.,1H),3.66(s,3H),2.57-2.47(m,1H),2.41-2.30(m,1H),2.25-2.16(m,2H),2.06(s,3H),1.96-1.64(m,9H),1.52-1.30(m,6H),1.25-1.05(m,6H),0.99(s,3H),0.93-0.88(m,6H),0.65(s,3H)。
实施例33E
氮气保护,零度下向二碘甲烷(438.0毫克,1.6毫摩尔)的二氯甲烷溶液中滴加二乙基锌(1M,3.3毫升),30分钟后,零度下滴加实施例33D化合物(150.0毫克,327.0微摩尔)的二氯甲烷(2毫升)溶液,20摄氏度下反应12小时。水(5毫升)加入反应体系,体系用盐酸溶液(1M)调至Ph=6,水层用二氯甲烷(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发得到实施例33E化合物(110.0毫克,71%)。1H NMR(CDCl3,400MHz)δ5.15-5.09(m,1H),3.68(s,3H),2.41-2.20(m,4H),2.13-2.08(m,3H),1.99(d,J=12.0Hz,1H),1.90-1.70(m,5H),1.44-1.02(m,15H),0.95-0.87(m,6H),0.84(s,3H),0.82(d,J=5.0Hz,1H),0.79-0.68(m,2H),0.67(s,3H),0.63(dd,J=4.0,8.8Hz,1H)。
实施例89
向实施例33E化合物(40.0毫克,84.3微摩尔)乙醇溶液(1毫升)加质量分数10%的氢氧化钾水溶液(1毫升),混合物70摄氏度下反应12小时。体系用盐酸溶液(1M)调至Ph=2,水层用乙酸乙酯(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发。残余物通过制备薄层板纯化(石油醚/乙酸乙酯=2/1)得到实施例89化合物(10.0毫克,28.36%)。1H NMR(CDCl3,400MHz)δ3.81-3.70(m,1H),2.58-2.43(m,1H),2.39(dd,J=5.1,10.2Hz,1H),2.31-2.19(m,2H),1.98-1.76(m,5H),1.72-1.55(m,6H),1.46(dd,J=5.5,10.5Hz,4H),1.23-1.02(m,6H),0.95-0.88(m,6H),0.82-0.78(m,3H),0.76-0.68(m,2H),0.68(s,3H),0.64(br.s.,1H),0.63-0.52(m,1H)。
路线34
实施例34A
向干燥的25毫升圆底烧瓶中加入干钯碳(50毫克,水<1%)和实施例33D化合物(600.0毫克,720.1微摩尔),再加入无水甲醇(5.0毫升)和四氢呋喃(5.0毫升),反应体系用氮气换气三次,然后再用氢气换气三次,反应液于氢气氛围中(15psi),25摄氏度搅拌48小时。反应液用硅藻土过滤,二氯甲烷/甲醇洗涤(10/1,20毫升),滤液浓缩得到实施例34A化合物(550.0毫克,91%产率)。1H NMR(400MHz,CHLOROFORM-d)δ5.13(br.s.,1H),3.68(s,3H),2.43-2.18(m,3H),2.06(s,3H),2.01-1.63(m,14H),1.55-1.15(m,25H),0.95(d,J=6.5Hz,6H),0.91(s,6H),0.88(d,J=2.3Hz,2H),0.70-0.66(m,3H).
实施例34B
以实施例35A(550.0毫克,1.3毫摩尔)为原料,合成操作如同实施例53,得到实施例34B化合物(400.0毫克,75.3%产率)。1H NMR(400MHz,CHLOROFORM-d)δ3.72(br.s.,1H),2.48-2.35(m,1H),2.28(ddd,J=6.4,9.5,15.7Hz,1H),2.02-1.87(m,3H),1.81(d,J=13.3Hz,3H),1.77-1.60(m,5H),1.55-1.41(m,7H),1.39-1.26(m,7H),1.20-1.13(m,3H),1.08-1.02(m,1H),0.98-0.95(m,4H),0.92(s,3H),0.90-0.85(m,2H),0.70-0.67(m,3H).
实施例90
操作同实施例2A,以实施例34B(100.0毫克,247.2微摩尔)为原料,进行酰化反应经纯化得到实施例90化合物(20.0毫克,16.8%产率)。1H NMR(400MHz,CHLOROFORM-d)δ3.72(br.s.,1H),3.32(s,3H),2.46-2.34(m,1H),2.30-2.18(m,1H),1.99-1.86(m,3H),1.85-1.77(m,3H),1.74-1.62(m,4H),1.56-1.40(m,8H),1.38-1.26(m,7H),1.22-1.16(m,3H),1.10-1.02(m,1H),0.97-0.93(m,4H),0.91(s,3H),0.90(d,J=2.0Hz,1H),0.88(d,J=3.0Hz,1H),0.71-0.66(m,3H).
路线35
实施例91
实施例35A
将氢氧化钠(79.6毫克,2.0毫摩)加入到实施例13A化合物(1.2克,2.0毫摩)的甲醇(15.0毫升)和水(1.5毫升)溶液中,并在25-30摄氏度搅拌18小时。反应完成后,溶剂浓缩至5毫升,并用乙酸乙酯稀释至12毫升后,用2M稀盐酸和柠檬酸酸化至pH=5-6,分层之后,有机相用饱和食盐水洗涤(25毫升×3),乙酸乙酯(20毫升×3)萃取,有机相用无水硫酸钠干燥,过滤浓缩得到实施例35A化合物(1.1克,纯度90%)。1H NMR(400MHz,CHLOROFORM-d)δ0.63(s,3H)0.81-0.97(m,10H)0.98-1.23(m,4H)1.28-1.49(m,9H)1.57-1.76(m,6H)1.76-1.98(m,9H)2.04(s,2H)2.09(s,2H)2.17-2.31(m,1H)2.34-2.47(m,1H)3.34-3.52(m,3H)3.54-3.64(m,1H)3.87-4.05(m,2H)4.44-4.58(m,1H)4.66-4.79(m,1H)
实施例35B
将二环己基碳二亚胺(1.3克,6.4毫摩)加入到实施例35A化合物(1.4克,2.1毫摩)和N-羟基琥珀酰亚胺(734.0毫克,6.4毫摩)在四氢呋喃(15.0毫升)和乙腈(1.5毫升)溶液中,在20-28摄氏度搅拌18小时。反应完成后,将混合物过滤,滤液真空旋干。所得粗品溶于12毫升N,N-二甲基甲酰胺中,并向其中加入氨水(910.0毫克,7.3毫摩)。反应液在50-60摄氏度搅拌20分钟。反应完成后,反应液冷却至室温,并用饱和食盐水洗涤(35毫升×2),乙酸乙酯(20毫升×2)萃取,有机相用无水硫酸钠干燥,过滤后低压旋干得到实施例35B化合物(1.8克,产率94.8%,纯度67%)。1H NMR(400MHz,CHLOROFORM-d)δ4.74(dd,J=3.8,7.8Hz,1H),4.52(dd,J=3.6,7.9Hz,1H),4.04-3.86(m,2H),3.70-3.58(m,1H),3.54-3.37(m,3H),3.26-3.16(m,2H),2.36-2.08(m,3H),2.02-1.73(m,19H),1.70-1.03(m,42H),0.99-0.80(m,10H),0.65(s,3H)
实施例35C
将实施例35B化合物(2.0克,3.4毫摩尔)溶于四氢呋喃(20.0毫升),零摄氏度时,分批加入四氢铝锂(1.0克,27.2毫摩尔),反应液于七十摄氏度搅拌十二小时。冷却至零摄氏度,向反应液中逐滴加入水(2毫升),用二氯甲烷/甲醇(10/1,30毫升×3)萃取。有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩。残留物经硅胶柱层析(预先用三乙胺(1毫升)于石油醚/乙酸乙酯中(10:1,10毫升)洗涤)得到实施例35C化合物(1.3克,69.1%产率)。1HNMR(400MHz,CHLOROFORM-d)δ4.76-4.68(m,1H),4.52(td,J=4.3,8.0Hz,1H),4.00-3.87(m,2H),3.60(d,J=10.3Hz,1H),3.51-3.36(m,3H),2.73-2.56(m,2H),1.99-1.91(m,2H),1.83(d,J=10.5Hz,4H),1.71-1.67(m,4H),1.52(d,J=3.5Hz,6H),1.39-1.29(m,5H),1.14-1.00(m,4H),0.93-0.91(m,2H),0.89(s,3H),0.86(d,J=5.8Hz,2H),0.63(s,3H).
实施例35D
将实施例35C化合物(200.0毫克,348.5微摩尔)溶于二氯甲烷(4.0毫升),依次加入三乙胺(70.5毫克,697.0微摩尔)和苯基磺酰氯(123.1毫克,697.0微摩尔),反应液于二十摄氏度搅拌十二小时。浓缩除去溶剂,残留物经薄层色谱分离得到实施例35D化合物(180.0毫克,72.3%产率)。1H NMR(400MHz,CHLOROFORM-d)δ7.89(d,J=7.3Hz,2H),7.62-7.52(m,3H),4.75(d,J=3.3Hz,1H),4.53(d,J=3.5Hz,1H),4.34(d,J=4.3Hz,1H),3.95(br.s.,2H),3.66-3.58(m,1H),3.48(br.s.,3H),3.06-2.88(m,2H),1.91-1.84(m,3H),1.73(br.s.,3H),1.55(br.s.,7H),1.41-1.24(m,8H),1.17-0.98(m,6H),0.91(br.s.,3H),0.61(d,J=2.3Hz,3H).
实施例91
将实施例35D化合物(140.0毫克,196.06微摩尔)溶于甲醇(5.0毫升),加入一水合对甲苯磺酸(37.3毫克,196.0微摩尔),反应液于二十摄氏度搅拌十二小时。浓缩除去溶剂,残留物经薄层色谱分离得到实施例91化合物(92.0毫克,85.9%产率)。H NMR(400MHz,CHLOROFORM-d)δ7.89(d,J=7.3Hz,2H),7.62-7.56(m,1H),7.56-7.49(m,2H),4.95(d,J=5.5Hz,1H),3.70(br.s.,1H),3.47-3.34(m,1H),3.01-2.81(m,2H),1.93(d,J=12.0Hz,1H),1.84-1.74(m,4H),1.68-1.57(m,3H),1.52-1.28(m,14H),1.20-1.06(m,5H),1.04-0.96(m,2H),0.92(br.s.,2H),0.89(br.s.,3H),0.85(d,J=6.5Hz,4H),0.62(s,3H).
实施例92和实施例93的制备参考实施例91的操作,通过路线35制备得到,所得结果如下:
路线36
实施例94
实施例36A
将三甲基硅基异氰酸酯(361.3毫克,3.1毫摩尔,415.35微升)加入至实施例35C(1.5g,2.61毫摩尔)的二氯甲烷(10.0毫升)溶液中。反应液在25摄氏度搅拌12小时。TLC(二氯甲烷/甲醇=10/1)显示反应完成。向反应液中加水5毫升,并用二氯甲烷(5毫升×3)萃取,合并有机层用食盐水10毫升(5毫升×2)洗涤,无水硫酸钠干燥,过滤浓缩得到实施例36A(1.4g,产率86.9%)。1H NMR(400MHz,CHLOROFORM-d)δ4.77-4.69(m,1H),4.60-4.47(m,2H),4.39(br.s.,2H),4.00-3.87(m,2H),3.60(d,J=10.3Hz,1H),3.52-3.38(m,3H),3.20-3.01(m,2H),2.10-1.75(m,9H),1.63-0.98(m,29H),0.96-0.82(m,11H),0.62(s,3H)
实施例94
参考实施例65的操作步骤,以实施36A为原料,经纯化得到实施例94化合物(692.0毫克,产率67.8%)。1H NMR(400MHz,CHLOROFORM-d)δ4.66(br.s.,1H),4.44(br.s.,1H),3.72(br.s.,1H),3.49-3.36(m,1H),3.14(dt,J=6.3,13.2Hz,2H),1.99(d,J=12.0Hz,1H),1.94-0.98(m,33H),0.97-0.87(m,9H),0.67(s,3H)
路线37
实施例95
实施例37A
将实施例35C化合物(200.0毫克,357.2微摩尔)溶于二氯甲烷(2毫升),加入三乙胺(72.3毫克,714.5微摩尔,99.0微升),于0摄氏度下,加入单草酰氯乙酯(97.6毫克,714.5微摩尔,79.9微升),溶于二氯甲烷(1毫升),反应液于30摄氏度搅拌十二小时。浓缩除去溶剂,向残留物中加入水(5毫升),乙酸乙酯萃取(10毫升×3)。有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩。残留物经薄层层析色谱分离得到实施例37A化合物(130.0毫克,54.0%产率)。1H NMR(400MHz,CHLOROFORM-d)δ7.11(d,J=4.8Hz,1H),4.77-4.64(m,1H),4.53-4.41(m,1H),4.37-4.25(m,4H),3.99-3.87(m,1H),3.63-3.54(m,1H),3.44(dd,J=5.5,10.8Hz,1H),3.36-3.20(m,2H),2.33-2.19(m,1H),1.98-1.90(m,2H),1.86-1.73(m,5H),1.60(d,J=8.0Hz,3H),1.51(d,J=3.0Hz,3H),1.38(s,4H),1.25(d,J=7.0Hz,3H),1.13-1.05(m,3H),0.92(s,3H),0.86(d,J=5.3Hz,2H),0.62(s,3H).
实施例95
操作例同实施例53以及实施例65化合物,以实施例37A(150.0毫克,222.6微摩尔)经两步合成,纯化得到了实施例95化合物(6.0毫克,9.1%产率)。1H NMR(400MHz,METHANOL-d4)δ3.67(br.s.,1H),3.34-3.34(m,1H),2.95-2.87(m,2H),2.03(d,J=12.0Hz,1H),1.93-1.73(m,6H),1.63-1.48(m,9H),1.39(br.s.,4H),1.26-1.14(m,4H),1.02(d,J=6.3Hz,3H),0.95-0.89(m,8H),0.74-0.68(m,3H).
路线38
实施例38A
向100毫升三颈烧瓶中加入二氯甲烷(10毫升),碳酸氢钠水溶液(292.8毫克,3.5毫摩尔),溶于水(5.0毫升)和实施例35C化合物(100.0毫克,174.2微摩尔),零摄氏度下一次性加入三光气(103.4毫克,348.5微摩尔),反应液于零摄氏度搅拌一小时。反应液倒入分液漏斗,分出有机层,水相用二氯甲烷萃取(20毫升×2)。有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩得到中间体A。零摄氏度下,(3S)-羟基吡咯(43.1毫克,348.5微摩尔)和三乙胺(35.2毫克,348.5微摩尔)加入到中间体A的二氯甲烷溶于中(5毫升),两小时后除去冰浴,反应液于三十摄氏度搅拌两小时。浓缩除去溶剂,残留物经薄层层析色谱分离得到实施例38A化合物(76.0毫克,63.5%产率)。1H NMR(400MHz,CHLOROFORM-d)δ4.76-4.68(m,1H),4.54-4.46(m,2H),4.24-4.12(m,1H),4.00-3.87(m,2H),3.62-3.56(m,1H),3.52-3.37(m,7H),3.23(br.s.,1H),3.15(br.s.,1H),2.06-1.93(m,4H),1.83(d,J=11.0Hz,4H),1.73-1.66(m,4H),1.48(br.s.,2H),1.44-1.36(m,5H),1.29-1.23(m,3H),1.13-1.03(m,3H),0.92(br.s.,2H),0.89(s,3H),0.88-0.85(m,3H),0.62(s,3H).
实施例96
以实施例38A(76.0毫克,110.6微摩尔)为原料,参考实施例65的操作步骤,经薄层层析色谱分离得到实施例96化合物(40.0毫克,69.7%产率)。1H NMR(400MHz,METHANOL-d4)δ4.43-4.38(m,1H),3.67(br.s.,1H),3.49-3.41(m,3H),3.34-3.33(m,1H),3.30(br.s.,1H),3.20-3.06(m,2H),2.02(qd,J=4.3,13.1Hz,2H),1.95-1.90(m,2H),1.86(br.s.,1H),1.80-1.72(m,3H),1.69-1.63(m,2H),1.59-1.53(m,4H),1.46-1.41(m,3H),1.37(d,J=2.0Hz,2H),1.31-1.31(m,3H),1.21-1.17(m,3H),1.11-1.07(m,2H),0.99(s,3H),0.92(s,3H),0.90(br.s.,3H),0.88(s,3H),0.71(s,3H).
路线39
实施例97
实施例39A
将实施例35C(1.3克,2.3毫摩尔)溶于四氢呋喃(12毫升),加入三乙胺(458.4毫克,4.5毫摩尔),再滴加氯乙基异氰酸酯(478.1毫克,4.5毫摩尔),溶于四氢呋喃(3毫升),反应液于三十摄氏度搅拌十二小时。加入水(5毫升),乙酸乙酯萃取(10毫升×3)。有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩。粗产物经薄层层析色谱分离得到实施例39A化合物(1.2克,77.8%产率)。1H NMR(400MHz,CHLOROFORM-d)δ5.03(br.s.,1H),4.79(br.s.,1H),4.72(d,J=4.3Hz,1H),4.51(dd,J=3.8,13.3Hz,1H),4.42(br.s.,1H),3.93(d,J=5.8Hz,2H),3.63(s,2H),3.58-3.53(m,4H),3.47(d,J=3.0Hz,2H),3.19-3.03(m,2H),1.83(d,J=10.3Hz,4H),1.52(br.s.,7H),1.44-1.36(m,5H),1.30-1.23(m,5H),1.10-1.03(m,2H),0.92(d,J=4.0Hz,2H),0.89(s,3H),0.71(s,3H).
实施例39B
将钠氢(63.6毫克,2.6毫摩尔)(65%于矿物油中)悬浮于四氢呋喃(25毫升),零摄氏度氮气保护下,逐滴加入实施例39A化合物(600.0毫克,883.1微摩尔),溶于四氢呋喃(5毫升)。一小时后除去冰浴,于三十摄氏度继续搅拌十一小时。加入水(5毫升),用一摩尔盐酸酸化(pH=5-6),乙酸乙酯萃取(20毫升×3)。有机层经水洗(10毫升),无水硫酸钠干燥,过滤和浓缩。粗产物经薄层层析色谱分离得到实施例39B化合物(360.0毫克,63.4%产率)。1HNMR(400MHz,CHLOROFORM-d)δ8.95(s,1H),4.72(d,J=4.3Hz,1H),4.51(dd,J=3.8,7.8Hz,1H),3.99-3.89(m,2H),3.83-3.77(m,1H),3.67-3.56(m,2H),3.53-3.39(m,4H),3.28(t,J=7.0Hz,1H),1.83(d,J=11.5Hz,4H),1.69(d,J=10.5Hz,5H),1.52(br.s.,6H),1.52-1.51(m,2H),1.42-1.36(m,4H),1.14-1.03(m,5H),0.89(br.s.,3H),0.87(d,J=3.3Hz,4H),0.63(s,3H)。
实施例97
以实施例39B化合物(360.0毫克,559.9微摩尔)为原料,合成操作例同实施例65,纯化得到实施例97化合物(200.0毫克,75.2%产率)。1H NMR(400MHz,METHANOL-d4)δ4.62(br.s.,1H),3.67(br.s.,1H),3.51-3.44(m,2H),3.43-3.37(m,2H),3.32-3.29(m,1H),3.13(t,J=7.0Hz,2H),2.03(d,J=12.3Hz,1H),1.97-1.72(m,6H),1.68-1.42(m,11H),1.32(d,J=12.3Hz,6H),1.23-1.07(m,4H),0.99(d,J=6.5Hz,3H),0.93(s,3H),0.90(d,J=3.3Hz,2H),0.72(s,3H).
路线40
实施例98
实施例40A
将实施例19B化合物(100.0毫克,223.4微摩尔)溶于二氯甲烷(2.0毫升),在0摄氏度时,加入三乙胺(33.9毫克,335.1微摩尔),再加入氯代草酸单乙酯(61.0毫克,446.7微摩尔),反应液于20摄氏度搅拌16小时。浓缩除去溶剂,残留物经薄层层析色谱分离得到实施例40A化合物(50.0毫克,91.29微摩尔,40.7%产率)。1H NMR(400MHz,CHLOROFORM-d)δ8.17(s,1H),8.09-8.04(m,1H),7.04(br.s.,1H),5.21(br.s.,1H),4.78-4.65(m,1H),4.37(q,J=7.2Hz,2H),3.52-3.36(m,1H),3.35-3.23(m,1H),2.05-1.87(m,3H),1.83-1.71(m,4H),1.59(s,3H),1.54-1.47(m,3H),1.41(t,J=7.2Hz,4H),1.34-1.27(m,4H),1.23-1.12(m,5H),1.00(d,J=6.5Hz,3H),0.98(s,3H),0.92(t,J=7.3Hz,3H),0.71-0.64(m,3H).
实施例98
将实施例40A化合物(50.0毫克,91.2微摩尔)溶于四氢呋喃(1.0毫升),甲醇(1.0毫升)和水(1.0毫升),加入一水合氢氧化锂(76.6毫克,1.8毫摩尔),反应液于25摄氏度搅拌十二小时。反应液用二氯甲烷/甲醇萃取(10/1,10毫升×3),有机层经水洗(10毫升),无水硫酸钠干燥和浓缩得到实施例98化合物(38.0毫克,89.7%产率)。1H NMR(400MHz,CHLOROFORM-d)δ7.32(br.s.,1H),3.71(br.s.,1H),3.42(d,J=3.8Hz,2H),3.37-3.23(m,1H),1.96(d,J=11.8Hz,1H),1.92-1.76(m,5H),1.73-1.56(m,5H),1.54-1.38(m,6H),1.37-1.25(m,7H),1.24-1.12(m,4H),0.99(d,J=6.5Hz,4H),0.92(br.s.,1H),0.90(s,3H),0.88(br.s.,1H),0.66(s,3H)。
实施例99的制备参考实施例98的操作,通过路线40制备得到,所得结果如下:
路线41
实施例100
实施例41A
向实施例2A化合物(500.0毫克,1毫摩尔)的四氢呋喃(5毫升)溶液中加入三乙胺(153.0毫克,1.5毫摩尔)和氯甲酸乙酯(167.0毫克,1.5毫摩尔),反应体系25摄氏度下反应2小时。体系冷却至摄氏度,硼氢化钠(210.0毫克,5.5毫摩尔)的甲醇(5毫升)溶液慢慢加入反应体系,0摄氏度下反应15分钟,25摄氏度下反应15分钟。0.2M的稀盐酸淬灭反应,水层用乙酸乙酯(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发,残余物通过柱色谱(石油醚/乙酸乙酯=4/1,二氯甲烷/乙酸乙酯=1/1)纯化得到实施例41A化合物(600.0毫克,粗品)。1H NMR(400MHz,CHLOROFORM-d)δ8.15(s,1H),8.04(s,1H),5.19(br.s.,1H),4.77-4.66(m,1H),3.66-3.57(m,2H),2.06-1.77(m,7H),1.45-1.06(m,21H),0.97-0.88(m,9H),0.66(s,3H).
实施例41B
零度下向实施例41A化合物(280.0毫克,605.0微摩尔),三苯基磷(476.0毫克,1.8毫摩尔)和咪唑(124.0毫克,1.8毫摩尔)的甲苯(4毫升)和乙腈(1毫升)溶液中加入碘(461.0毫克,1.8毫摩尔),反应体系25℃下反应3小时。饱和的亚硫酸钠溶液(10毫升)加入反应体系,水层用乙酸乙酯(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发,残余物通过柱色谱纯化(石油醚/乙酸乙酯=20/1)得到标题化合物41B化合物(250.0毫克,70%)。1H-NMR(CDCl3,400MHz)δ8.16(s,1H),8.07-8.02(m,1H),5.20(br.s.,1H),4.76-4.66(m,1H),3.24-3.08(m,2H),2.01-1.72(m,10H),1.46-1.06(m,17H),0.97-0.89(m,9H),0.66(s,3H).
实施例41C
向实施例41B化合物(400.0毫克,699微摩尔)的N,N-二甲基甲酰胺(5毫升)溶液中加入氰化钠(171.0毫克,3.5毫摩尔),反应体系100摄氏度下反应2小时。水(10毫升)加入反应体系,水层用乙酸乙酯(10毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发得到标题化合物41C化合物(225.0毫克,68%),1H NMR(400MHz,CHLOROFORM-d)δ8.15(d,J=3.0Hz,1H),8.04(s,1H),5.19(br.s.,1H),4.77-4.66(m,1H),3.46(d,J=4.5Hz,1H),2.37-2.25(m,2H),2.01-1.66(m,10H),1.39-1.03(m,12H),0.98-0.87(m,9H),0.66(d,J=1.5Hz,3H)及3位脱甲酰基的产物(75毫克,24%),1H NMR(400MHz,CHLOROFORM-d)δ=8.14(s,1H),5.19(br.s.,1H),3.46(br.s.,1H),2.30(dt,J=3.8,6.9Hz,2H),2.02-1.66(m,11H),1.43-1.03(m,17H),0.94-0.86(m,9H),0.66(s,3H)。
实施例41D
实施例41C化合物(100.0毫克,212微摩尔)的30%氢氧化钾的甲醇:水(体积比1:1)(10毫升)溶液90摄氏度下反应16小时。水(10毫升)和乙酸乙酯(10毫升)加入反应体系,有机层用饱和氢氧化钾溶液(20毫升)洗涤,合并水层,水层用4M盐酸调至Ph=4,水层用乙酸乙酯(20毫升×3)萃取,合并有机层,硫酸钠干燥,过滤并蒸发得到标题化合物41D化合物(85.0毫克,92%),1H NMR(400MHz,CHLOROFORM-d)δ3.71(br.s.,1H),3.52-3.32(m,1H),2.33(qt,J=7.9,16.0Hz,2H),2.00-1.33(m,22H),1.22-1.00(m,5H),0.96-0.83(m,8H),0.66(s,3H)。
实施例100
25摄氏度下向实施例41D化合物(50.0毫克,115.0微摩尔)的二氯甲烷(1毫升)溶液中加环己基羰二酰亚胺(36.0毫克,172微摩尔),N,N-二甲基吡啶(14.0毫克,115微摩尔)和甲基磺酰胺(16.0毫克,172微摩尔),反应体系25摄氏度下反应12小时。水(5毫升)加入反应体系,体系用盐酸(1M)调至Ph=2,乙酸乙酯(10毫升×3)萃取,有机层经无水硫酸钠干燥,过滤,浓缩。残余物通过制备薄层板纯化(二氯甲烷/甲醇=20/1)得实施例100化合物(15.0毫克,25%产率)。1H NMR(400MHz,CHLOROFORM-d)δ3.70(br.s.,1H),3.47-3.36(m,1H),3.28(s,3H),2.36-2.23(m,2H),1.95-1.40(m,20H),1.26-1.05(m,7H),0.95-0.88(m,9H),0.65(s,3H)。
路线42
实施例101
实施例42A
氮气保护下,向参考例1A化合物(35.0克,89.6毫摩尔)的二氧六环(550毫升)溶液中加入一水对甲苯磺酸(1.5克,8.9毫摩尔)和二氢吡喃(11.3克,134.4毫摩尔)。TLC检测反应完毕,在50摄氏度下氢化2小时(50psi)。将溶剂部分蒸发,加水(50毫升),用乙酸乙酯(50毫升×3)萃取。合并的有机层用盐水(50毫升)洗涤后,经硫酸钠干燥,过滤并蒸发,残余物通过柱色谱纯化得到标题化合物42A化合物(33.0克,77.5%产率)。1H NMR(400MHz,CHLOROFORM-d)δ4.67-4.76(m,1H),3.81-3.94(m,1H),3.39-3.65(m,2H),2.76-2.90(m,1H),2.18-2.43(m,4H),1.62-2.01(m,12H),1.29-1.59(m,12H),1.07-1.14(m,2H),0.92(d,J=6.27Hz,3H),0.64(s,3H).
实施例42B
零下78摄氏度氮气保护下,向四氢呋喃(100.0毫升)滴加二异丙基胺基锂(2摩尔每升,6.74毫升),六甲基磷酸三胺(2.4克,13.4毫摩尔,2.4毫升)滴加到上述溶液中,滴加完后保持零下78摄氏度搅拌30分钟,然后化合物42A化合物(2.0克,4.2毫摩尔)的四氢呋喃溶液滴加到上述溶液中并保持零下78摄氏度搅拌30分钟,最后碘甲烷(4.9克,34.5毫摩尔)的四氢呋喃(8毫升)溶液缓慢加入反应器中,之后升到室温搅拌过夜。加饱和氯化铵(10毫升)摧灭,用10%柠檬酸调pH到4,加入水,20毫升,用乙酸乙酯萃取(200毫升×3),将合并的有机层用饱和食盐水(100毫升)洗一次,有机相用无水硫酸钠干燥,过滤并蒸发得到标题化合物42B化合物(2.1克,粗品),直接用于下一步反应。
实施例42C
向实施例42B化合物(2.1克,4.2毫摩尔)的甲醇溶液加对甲苯磺酸(73.1毫克,424.0微摩尔)。反应加热到80摄氏度搅拌2小时,旋蒸蒸出主要溶剂(50摄氏度)加入水2毫升,用乙酸乙酯萃取(5毫升×3),将合并的有机层用饱和碳酸氢钠(2毫升)饱和食盐水(5毫升)洗,有机相用无水硫酸钠干燥,过滤并蒸发,剩余物过柱纯化(石油醚/乙酸乙酯=10/1到3/1)得到标题化合物42C化合物(350.0毫克,17.7%产率)。1HNMR(400MHz,CHLOROFORM-d)δ0.61-0.73(m,3H)0.93(d,J=6.53Hz,3H)1.01(dd,J=12.05,6.53Hz,1H)1.09-1.24(m,7H)1.26-1.38(m,6H)1.40-1.52(m,5H)1.62-1.87(m,6H)1.89-2.04(m,2H)2.06-2.15(m,1H)2.16-2.27(m,2H)2.31-2.40(m,1H)2.57(t,J=11.29Hz,1H)3.59(br.s.,1H)3.67(s,3H)。
实施例42D
向实施例42C化合物(340.0毫克,812.21微摩尔)加入氢氧化钠(105.5毫克,2.6毫摩尔)的水(60.0毫升)溶液,加热到80摄氏度,硼氢化钠(184.3毫克,4.8毫摩尔)分批加入,反应升温到100摄氏度搅拌8小时,冷却到15摄氏度,加饱和氯化铵(100毫升)摧灭,用1摩尔每升的稀盐酸调pH到2~3,用乙酸乙酯萃取(100毫升×3),将合并的有机层用饱和食盐水(100毫升)洗,有机相用无水硫酸钠干燥,过滤并蒸发,剩余物过柱纯化(石油醚/乙酸乙酯=2/1→1/2、加少量乙酸)得到标题化合物42D化合物(230.0毫克,62.6%产率)。1HNMR(400MHz,CHLOROFORM-d)δppm 0.66(s,3H)0.86-1.05(m,11H)1.08-1.29(m,6H)1.30-1.54(m,7H)1.59-2.00(m,11H)2.26(ddd,J=15.94,9.41,6.27Hz,1H)2.35-2.47(m,1H)3.36-3.47(m,1H)3.60(br.s.,1H)
实施例101
20℃氮气保护下,混合物甲烷磺酰胺(16.4毫克,172.1微摩尔)、实施例42D化合物(70.0毫克,172.1微摩尔)、二环己基碳二亚胺(71.0毫克,344.3微摩尔)和二异丙基乙胺(22.2毫克,172.1微摩尔)在二氯甲烷(2毫升)中搅拌10小时,加入水10毫升,用乙酸乙酯萃取(15毫升×3),将合并的有机层用饱和食盐水(10毫升)洗一次,有机相浓缩得到实施例101化合物(15.0毫克,16.2%产率)。1HNMR(400MHz,CHLOROFORM-d)δppm 0.66(s,3H)0.88-1.03(m,10H)1.07-1.19(m,7H)1.29-1.42(m,7H)1.45-1.74(m,11H)1.77-2.03(m,14H)2.25(ddd,J=15.75,9.72,6.15Hz,1H)2.34-2.47(m,1H)3.29(s,3H)3.43(dd,J=10.04,5.02Hz,2H)3.59(br.s.,1H)4.40(br.s.,1H)。
路线43
实施例102
实施例43A
零下30摄氏度氮气保护下向实施例17A化合物(240.0毫克,534.9微摩尔)的无水四氢呋喃(15毫升)溶液中加入四氯磷酸酯(200毫克,803.6微摩尔),并搅拌2.5小时。溶剂旋干后加水(10毫升),过滤,滤饼溶于甲醇并减压旋干得到粗品实施例43A化合物(240.0毫克,80.6%收率)。1H NMR(400MHz,METHANOL-d4)δ8.21(s,1H),5.18(br.s.,1H),4.03(td,J=7.7,14.8Hz,2H),3.46(br.s.,2H),2.05(d,J=12.5Hz,1H),1.93-1.80(m,6H),1.75-1.60(m,7H),1.54(br.s.,3H),1.43-1.06(m,15H),1.01(d,J=6.5Hz,3H),0.99(s,3H),0.93(t,J=7.3Hz,3H),0.73(s,3H)
实施例102
参考实施例2的操作步骤,以实施例43A化合物为原料(240.0毫克,479.4微摩尔)纯化得到实施例102化合物(200.0毫克,79.4%收率)。1H NMR(400MHz,METHANOL-d4)δ4.03(td,J=7.7,15.8Hz,2H),3.68(br.s.,1H),3.47(br.s.,1H),2.04(d,J=11.8Hz,1H),1.98-1.71(m,8H),1.67-1.48(m,9H),1.34(br.s.,7H),1.26-1.09(m,4H),1.02(d,J=6.5Hz,3H),0.99(br.s.,1H),0.96-0.90(m,6H),0.73(s,3H).
路线44
实施例103
实施例44A
将实施例21A化合物(2.0克,4.6毫摩尔)溶于甲酸(24.4克,530.1毫摩尔,再加入高氯酸(4.6毫克,46.2微摩尔),反应液于25摄氏度搅拌十二小时。浓缩除去溶剂,残留物经柱层析硅胶得到实施例44A化合物(700.0毫克,32.9%产率)。1H NMR(400MHz,CHLOROFORM-d)δ8.15(s,1H),5.32-5.21(m,1H),3.68(s,3H),2.87-2.74(m,1H),2.47-2.34(m,2H),2.29-2.19(m,3H),2.11-2.01(m,3H),1.94-1.76(m,6H),1.72-1.66(m,1H),1.58-1.40(m,6H),1.36-1.12(m,9H),1.07(s,3H),0.98-0.89(m,7H),0.72(br.s.,3H).
实施例44B
将实施例44A化合物(80.0毫克,173.6微摩尔)溶于二氯甲烷(3.0毫升),在25摄氏度,氮气保护下,加入三溴化吡啶盐(55.5毫克,173.6微摩尔),反应液于40摄氏度搅拌四小时。向反应液中加入二氯甲烷(25毫升),有机层经水洗(10毫升),无水硫酸钠干燥和浓缩。残留物经薄层色谱柱层析分离得到实施例44B化合物(40.0毫克,42.69%产率)。1H NMR(400MHz,CHLOROFORM-d)δ8.13(s,1H),5.34-5.21(m,1H),4.79(dd,J=5.1,14.2Hz,1H),3.71-3.59(m,3H),3.05-2.93(m,1H),2.69(dd,J=5.3,13.8Hz,1H),2.53(dd,J=4.5,14.8Hz,1H),2.43-2.14(m,3H),2.00-1.79(m,5H),1.71-1.62(m,2H),1.53-1.21(m,9H),1.17-1.13(m,2H),1.08(s,2H),0.95-0.80(m,7H),0.74-0.66(m,3H).
实施例44C
将实施例44B化合物(100.0毫克,185.3微摩尔)和硫代尿(28.2毫克,370.6微摩尔)溶于吡啶中(2.0毫升),反应液于90摄氏度搅拌十二小时。除去溶剂,向残留物中加入水(5毫升),用乙酸乙酯萃取(10毫升×3)。所得有机层经水洗(10毫升),无水硫酸钠干燥和浓缩。残留物经薄层色谱柱层析分离得到实施例44C化合物(45.0毫克,47.0%产率)。1H NMR(400MHz,CHLOROFORM-d)δ8.15(br.s.,1H),6.95(br.s.,1H),5.35-5.20(m,1H),3.67(s,3H),3.10(br.s.,1H),2.92-2.73(m,1H),2.54-2.16(m,4H),2.05-1.61(m,9H),1.47-1.27(m,9H),1.08(d,J=9.8Hz,4H),0.91(d,J=6.5Hz,4H),0.69-0.62(m,3H).
实施例103
参考实施例2的操作步骤,以实施例44C化合物为原料(45.0毫克,87.1微摩尔)纯化得到实施例103化合物(19.0毫克,45.9%产率,黄色固体)。1H NMR(400MHz,METHANOL-d4)δ3.76(br.s.,1H),3.48(dd,J=10.9,15.2Hz,1H),2.77(d,J=16.6Hz,1H),2.44-2.30(m,2H),2.25-2.18(m,2H),2.01-1.96(m,1H),1.95-1.88(m,1H),1.84-1.74(m,3H),1.67-1.61(m,2H),1.55-1.47(m,3H),1.40-1.29(m,5H),1.20-1.15(m,3H),1.12(s,3H),1.01-0.95(m,6H),0.94-0.86(m,5H),0.73(s,3H).
实验例1:体外研究
FXR生化实验实验目的:
通过均相邻近发光放大实验(alphascreen)检测化合物对FXR结合反应的激活作用。
实验材料:
1.蛋白:谷胱甘肽-S-转移酶标记的FXR人源蛋白(Invitrogen)
2.共激活因子:生物素标记的类固醇受体辅活化子(Anaspec)
3.检测试剂:均相邻近发光放大实验(alphascreen)检测试剂盒(PerkinElmer)
实验方法:
1.化合物稀释:将待测化合物制备为40μL的DMSO溶液,随后将化合物3倍稀释至10个浓度点。参照化合物制备为400μM的DMSO溶液,随后以1.5倍稀释至10个浓度点。将稀释好的DMSO溶液以每孔150nL的体积加入384孔板的微孔中。
2.将谷胱甘肽-S-转移酶标记的FXR人源蛋白和生物素标记的类固醇受体辅活化子配置浓度分别为0.4nM和30nM的混合溶液。以每孔15μL的体积加入384孔板的微孔中。室温孵育1小时。
4.将均相邻近发光放大实验(alphascreen)检测试剂盒中的受体小球混合液稀释125倍,以每孔7.5ul体积加入384孔板的微孔中。实验过程避光操作。室温孵育1小时。
5.将均相邻近发光放大实验(alphascreen)检测试剂盒中的供体小球混合液稀释125倍,以每孔7.5ul体积加入384孔板的微孔中。实验过程避光操作。室温孵育1小时。
6.EC50测试:采用Envision于680nm波长处激发,读取520-620nm处的吸收信号。
7.分析数据:用Prism 5.0来分析数据,计算化合物的激活作用EC50值。再将化合物的最高信号值与参照化合物的最高信号值作比值得出化合物的激活效力百分数(Efficacy)。
FXR细胞实验
实验目的:
通过β-内酰胺酶报告基因技术检测化合物对细胞功能活性的影响。
实验材料:
1.细胞系:FXR HEK 293T DA
2.细胞培养基:DMEM培养基添加10%血清和Penicillin/Streptomycin(1×)
实验方法:
1.化合物稀释:将待测化合物制备为100μM的DMSO溶液,随后将化合物3倍稀释至10个浓度点。参照化合物制备为100μM的DMSO溶液,随后以1.3倍稀释至10个浓度点。将稀释好的DMSO溶液以每孔200μL的体积加入384孔板的微孔中。
2.细胞接种:将FXR HEK 293T DA细胞复苏,用培养基重悬,稀释至密度为5×105个/mL,以每孔40μL的体积加入384孔板的微孔中。
3.将384微孔板于37℃,5%CO2条件下培养16小时。
4.将6μL的1mM LiveBLAzerTM-FRET B/G(CCF4-AM)底物与60μL的B溶液和934μL的C溶液混合,以每孔8μL的体积加入384孔板的微孔中。
5.将384微孔板室温避光孵育2小时。
6.EC50测试:采用Envision于409nm波长处激发,读取460和530nm处的吸收信号。
7.分析数据:用Prism 5.0来分析数据,计算化合物的激活作用EC50值。再将测试化合物的最高信号值与参照化合物(鹅去氧胆酸)的最高信号值作比值得出化合物的激活效力百分数(Efficacy)。
表1检测生化实验测试结果以及细胞实验测试结果EC50:
实验例2:体内研究
单独给药小鼠药代:
12只C57BL/6J雄性小鼠随机分为两组,6只每组。第一组为静脉组,为尾静脉脉注射给药2mg/kg、(溶媒为10%HPbCD水溶液,药物溶解度不理想时,则会加入助溶剂);第二组为口服组,灌胃给药10mg/kg、10mL/kg(溶媒为0.5%HPMC水溶液)。静脉组给药后0.083、0.25、0.5、1、2、4、6、8和24小时采集血浆(K2-EDTA为抗凝)样品;口服组给药后0.25、0.5、1、2、4、6、8和24小时采集血浆样品。每组6只动物,一个时间点采集3个动物血样,第1批3只动物与第2批3只动物交错采样。使用LC-MS/MS进行血浆样品分析。获得血浆浓度与时间作图,并使用Phoenix WinNonlin 6.3计算PK参数。
表2
ah,L/kg,mL/min/kg,nM.h;bnM,h,nM.h,%
盒式给药小鼠肝血比实验:
6只C57BL/6J雄性小鼠为一组,为口服组,制剂中含有5种研发药物,灌胃给药2mg/kg/化合物(溶媒为0.5%HPMC水溶液)。5个化合物首先分别溶于溶媒中,通过超声或者斡旋,分别形成1mg/mL溶液(澄清溶液或者混悬液),然后五种化合物溶液等体积混合(1:1:1:1:1,v:v:v:v:v)于一个玻璃瓶中。灌胃口服给药后,3只动物于给药后0.5小时采集血浆和肝组织样品;另外3只动物于给药后3小时采集相应样品。肝组织采集后,使用冰冷匀浆缓冲液(甲醇:15mM PBS缓冲液(pH 7.4)=1:2,v:v)按照肝重量:匀浆缓冲液体积=1:3进行匀浆。使用提前开发的五合一的LC-MS/MS分析方法进行血浆和肝组织样品分析。获得血浆浓度以及肝组织匀浆液浓度,并使用Excel计算肝组织与血浆浓度比值。
表3
结论:如表3中所示,口服给予相同剂量列表中本发明化合物,0.5小时以及3小时药物肝脏中的浓度均高于对照化合物,肝/血浓度比也高于对照化合物,表现出显著的效果。
Claims (10)
1.式Ⅴ所示化合物、其互变异构体、其立体异构体或其药学上可接受的盐:
其中,
R4选自H、或选自任选被1、2、3、4或5个R取代的C1-3烷基、C3-10环烷基、3~6元杂环烷基、5~6元芳基或5~6元杂芳基;
R5选自H、卤素、OH、NH2、SH、CN,或选自任选被1、2、3、4或5个R取代的C1-3烷基或C1-3烷氧基;
R6选自H或OH;
n选自0、1或2;
L选自:单键、-C(=O)-、-C(=O)S-、-C(=O)N(RL)S(=O)2(C(RL)2)0-2-、-C(=O)N(C(RL)3)S(=O)2-、-N(RL)C(=O)O(C(RL)2)0-2-、-N(RL)C(=O)N(RL)(C(RL)2)0-2-、-OC(=O)N(RL)-、-OS(=O)2N(RL)-、-N(RL)C(=S)N(RL)-、-N(RL)C(=S)-、-P(=O)(OEt)O-、-S(=O)2N(RL)-、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(RL)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(ORL)O-;
上述RL选自H,或选自任选被1、2、或3个R取代的C1-3烷基,优选RL选自H或C1-3烷基;
上述R分别独立地选自卤素、CN、OH、NH2、SH,或任选被1、2、3、4或5个R’取代的:C1-3烷基、C1-3杂烷基和/或
任选地,任何一个RL与R4连接在一起形成一个任选被1、2、3、4、或5个R取代的4~6元环;
上述R’选自卤素、CN、OH、NH2、SH、Me或三氟甲基;
条件是,当R4选自C1-3烷基时,R不选自OH和NH2。
6.根据权利要求1所述的化合物、其互变异构体、其立体异构体或其药学上可接受的盐,其特征在于,L选自单键、-C(=O)-、-C(=O)S-、-C(=O)NHS(=O)2(CH2)0-2-、-C(=O)N(CH3)S(=O)2-、-NHC(=O)O(CH2)0-2-、-NHC(=O)N(RL)(CH2)0-2-、-OC(=O)NH-、-OS(=O)2NH-、-NHC(=S)NH-、-NHC(=S)-、-P(=O)(OEt)O-、-S(=O)2NH-、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(RL)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(ORL)O-;优选地,L选自单键、-C(=O)-、-C(=O)S-、-C(=O)NHS(=O)2-、-C(=O)NHS(=O)2CH2-、-C(=O)NHS(=O)2(CH2)2-、-C(=O)N(CH3)S(=O)2-、-NHC(=O)O-、-NHC(=O)OCH2-、-NHC(=O)O(CH2)2-、-NHC(=O)NH-、-NHC(=O)NHCH2-、-NHC(=O)NH(CH2)2-、-OC(=O)NH-、-OS(=O)2NH-、-NHC(=S)NH-、-NHC(=S)-、-P(=O)(OEt)O-、-S(=O)2NH、-C(=O)NHS(=O)2NH-、-C(=O)NHS(=O)2NHCH2-、-C(=O)NHS(=O)2N(CH3)-、-C(=O)NHS(=O)2NHC(=O)-、-NHS(=O)2-、-NHC(=O)C(=O)O-或-OP(=O)(OMe)O-。
10.药物组合物,其包含治疗有效量的权利要求1-9中任一项权利要求所述的化合物、其互变异构体、其立体异构体或其药学上可接受的盐,以及一种或多种药学上可接受的载体或赋形剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015102142603 | 2015-04-29 | ||
CN201510214260 | 2015-04-29 | ||
CN201680024495.9A CN107531743B (zh) | 2015-04-29 | 2016-04-29 | 鹅去氧胆酸衍生物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680024495.9A Division CN107531743B (zh) | 2015-04-29 | 2016-04-29 | 鹅去氧胆酸衍生物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111574577A true CN111574577A (zh) | 2020-08-25 |
Family
ID=57198167
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680024495.9A Active CN107531743B (zh) | 2015-04-29 | 2016-04-29 | 鹅去氧胆酸衍生物 |
CN202010345654.3A Pending CN111574577A (zh) | 2015-04-29 | 2016-04-29 | 鹅去氧胆酸衍生物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680024495.9A Active CN107531743B (zh) | 2015-04-29 | 2016-04-29 | 鹅去氧胆酸衍生物 |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN107531743B (zh) |
TW (1) | TW201704251A (zh) |
WO (1) | WO2016173524A1 (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2017118569A (ru) * | 2014-11-06 | 2018-12-06 | Энанта Фармасьютикалс, Инк. | Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения |
US10208081B2 (en) * | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
KR20170099909A (ko) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
SG11201706089RA (en) | 2015-02-11 | 2017-09-28 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
RU2712099C2 (ru) | 2015-03-31 | 2020-01-24 | Энанта Фармасьютикалс, Инк. | Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения |
CN107250150B (zh) * | 2015-04-28 | 2019-11-22 | 江苏豪森药业集团有限公司 | 胆酸衍生物及其制备方法和医药用途 |
EP3310801B1 (en) * | 2015-06-19 | 2021-04-07 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
DK3310801T3 (da) | 2015-06-19 | 2021-06-21 | Intercept Pharmaceuticals Inc | Tgr5-modulatorer og fremgangsmåder til anvendelse deraf |
CN106478756A (zh) * | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技(武汉)有限公司 | Oca-e单晶及其制备方法和用途 |
WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
CA3027761A1 (en) * | 2016-07-13 | 2018-01-18 | Jiangsu Hengrui Medicine Co., Ltd. | Method for manufacturing obeticholic acid and intermediate thereof |
US10584145B2 (en) | 2016-11-29 | 2020-03-10 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
CN108218945B (zh) * | 2016-12-15 | 2021-05-28 | 宁波百纳西药业有限公司 | 去氧胆酸衍生物、其制备方法、药物组合物及用途 |
CN106749472B (zh) * | 2016-12-30 | 2019-02-22 | 江苏开元医药化工有限公司 | 一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法 |
WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
CN106986910A (zh) * | 2017-04-19 | 2017-07-28 | 成都百特万合医药科技有限公司 | 奥贝胆酸中间体的制备方法 |
CN109134572A (zh) * | 2017-06-19 | 2019-01-04 | 中国科学院上海药物研究所 | 胆酸衍生物及其制备方法和用途 |
EP3431486A1 (en) * | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
CN110869381B (zh) * | 2017-07-26 | 2021-11-19 | 正大天晴药业集团股份有限公司 | 甾体类衍生物fxr激动剂的制备方法 |
CN107383139A (zh) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法 |
US11111265B2 (en) | 2017-11-02 | 2021-09-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing cholic acid compound |
US11028111B2 (en) | 2017-12-19 | 2021-06-08 | Xi' An Biocare Pharma Ltd. | Compound for treating metabolic diseases and preparation method and use thereof |
CN107987116B (zh) * | 2018-01-17 | 2021-01-05 | 中国药科大学 | 一类鹅去氧胆酸衍生物、其制备方法和医药用途 |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
CN111285914B (zh) * | 2018-12-10 | 2023-02-17 | 江西青峰药业有限公司 | 一种奥贝胆酸的制备方法 |
CN109762043B (zh) * | 2019-03-06 | 2020-07-24 | 华南理工大学 | 鹅去氧胆酸及其制备方法 |
EP3965748A4 (en) * | 2019-05-10 | 2023-02-01 | President and Fellows of Harvard College | SMALL MOLECULE MODULATORS OF GUEST BACTERIAL BILE ACID METABOLISM |
CN112824425B (zh) * | 2019-11-21 | 2023-10-03 | 成都西岭源药业有限公司 | 一种6-位烯基取代胆酸化合物及其制备方法和应用 |
CN112898368B (zh) * | 2019-12-03 | 2023-08-18 | 中国科学院成都有机化学有限公司 | 一种奥贝胆酸中间体的制备方法 |
CN113493485A (zh) * | 2020-04-08 | 2021-10-12 | 西安奥立泰医药科技有限公司 | 胆汁酸衍生物盐、其晶型结构及它们的制备方法和应用 |
TW202333741A (zh) * | 2021-11-15 | 2023-09-01 | 大陸商海湃泰克(北京)生物醫藥科技有限公司 | 多環化合物及其方法 |
WO2023192221A1 (en) * | 2022-03-29 | 2023-10-05 | Bilayer Therapeutics, Inc. | Forms and compositions of sodium chenodeoxycholate |
CN116497082B (zh) * | 2023-06-27 | 2023-09-29 | 华南理工大学 | 一种化学-酶法合成3α,7α,24R-三羟基胆甾醇的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101395170A (zh) * | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
JP2013206716A (ja) * | 2012-03-28 | 2013-10-07 | Fujifilm Corp | 光電変換素子及び色素増感太陽電池 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
WO2016086115A1 (en) * | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
CN104672290B (zh) * | 2015-01-05 | 2017-06-06 | 北京普禄德医药科技有限公司 | 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途 |
-
2016
- 2016-04-29 CN CN201680024495.9A patent/CN107531743B/zh active Active
- 2016-04-29 WO PCT/CN2016/080635 patent/WO2016173524A1/zh active Application Filing
- 2016-04-29 TW TW105113465A patent/TW201704251A/zh unknown
- 2016-04-29 CN CN202010345654.3A patent/CN111574577A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101395170A (zh) * | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
JP2013206716A (ja) * | 2012-03-28 | 2013-10-07 | Fujifilm Corp | 光電変換素子及び色素増感太陽電池 |
Non-Patent Citations (3)
Title |
---|
PONNUSAMY BABU等: "Micellar aggregates and hydrogels from phosphonobile salts", 《ORGANIC&BIOMOLECULAR CHEMISTRY》, vol. 3, no. 20, 8 September 2005 (2005-09-08), pages 3695 - 3700, XP055230783, DOI: 10.1039/b504656d * |
ROBERTO PELLICCIARI等: "Back Door Modulation of the Farnesoid X Receptor: Design, Synthesis, and Biological Evaluation of a Series of Side Chain Modified Chenodeoxycholic Acid Derivatives", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 49, 15 June 2006 (2006-06-15), pages 4210 * |
ROBERTO PELLICCIARI等: "Bile Acid Derivatives as Ligands of the Farnesoid X Receptor. Synthesis, Evaluation, and Structure-Activity Relationship of a Series of Body and Side Chain Modified Analogues of Chenodeoxycholic Acid", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 47, no. 18, 23 July 2004 (2004-07-23), pages 4565, XP002669041, DOI: 10.1021/JM049904B * |
Also Published As
Publication number | Publication date |
---|---|
WO2016173524A1 (zh) | 2016-11-03 |
CN107531743A (zh) | 2018-01-02 |
TW201704251A (zh) | 2017-02-01 |
CN107531743B (zh) | 2020-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107531743B (zh) | 鹅去氧胆酸衍生物 | |
AU2021202018B2 (en) | Steroid derivative fxr agonist | |
CN110662743B (zh) | 作为fxr受体激动剂的内酰胺类化合物 | |
US10947264B2 (en) | Process for preparation of sulfonylurea bile acid derivatives | |
WO2016172543A1 (en) | Methods for the synthesis of ceragenins | |
CA3155885A1 (en) | Substituted macrocyclic compounds and related methods of treatment | |
CN108025994A (zh) | 用于制备胆汁酸及其衍生物的方法 | |
TW202227433A (zh) | 中環或大環之經苄基取代的雜環衍生物及相關用途 | |
CA3030551A1 (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides | |
US9745338B2 (en) | Pro-drug forming compounds | |
EP0338735B1 (en) | Process for optically active 3-(methane-sulfonyloxy)thioland and analogs | |
CA3147078A1 (en) | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives | |
WO1994010185A1 (en) | Erythromycin derivative | |
WO2021100730A1 (ja) | ピロリジン化合物の製造方法 | |
EA038580B1 (ru) | Агонист fxr, представляющий собой производное стероидов | |
EP3285875A1 (en) | Methods for the synthesis of ceragenins | |
CN116789636A (zh) | 双功能化合物及其制备方法、药物组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |